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EXERCISE ASSOCIATED FACTORS AFFECTING 
CARDIOVASCULAR HEALTH AND FUNCTION: 
FROM MYOCYTE SIGNALING TO GENETIC 
VARIATIONS 
 
Introduction 
The National Cholesterol Education Program‘s Adult Treatment Panel III report 
(ATP III)1 identified the metabolic syndrome (MS) as a multiplex risk factor for 
cardiovascular disease (CVD) that is deserving of more clinical attention. The MS is 
characterized by a group of metabolic risk factors in one person. They include: 
abdominal obesity, atherogenic dyslipidemia, elevated blood pressure, insulin resistance 
or glucose intolerance, prothrombotic state, proinflammatory state [1]. A meta-Analysis 
study demonstrates that the MS is associated with a 2-fold increase
 
in cardiovascular 
outcomes and a 1.5-fold increase in all-cause
 
mortality [2]. The prevalance of the MS 
across the U.S. population age 20-70 years was reported to be 23.7%, [range from 6.7-
43.5%] with an increase in prevalance correlated with age [3].  A similar trend has also 
been reported in Europe with a prevalence rate of 37% across a population aged 30-89 
years, [range from 10.3-58.4%] with an increase in prevalance correlated with age [4].   
It is widely recognized that the most successful way of treated the MS is its prevention, 
with the most effective way of prevention being adopting a healthy lifestyle. Non 
excessive eating and regular physical activity are the factors of healthy living that have 
the strongest correlation to the prevention of the MS and subsequently CVD  and heart 
failure [5]. Heart failure represent a major cause of morbidity and mortality in 
industrialized countries.   
The preventative mechanism of physical activity with regards to MS and CVD 
does not solely depend on the prevention of caloric overconsumption by increasing 
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caloric expenditure, but also causes various cellular adaptations that have been 
demonstrated to be cardioprotective.  The exact mechanisms of the exercise induced 
adaptations is not lucid, but recent studies have delineated two means of signaling by 
which the adaptations occur (1) substrate availability signaling (metabolic stress) (2) 
hormone-receptor signaling. We have decided to specifically investigate two metabolic 
signaling enzymes [AMP-activated kinase (AMPK) and Sirtuin 1(SIRT1)] and two 
hormones [Adiponectin and Adrenergic stimulation] that are at the moment frequently 
investigated as potential targets to cardiac protection.  
 
AMP-activated kinase (AMPK)  
5‘Adenosine mono-phosphate protein kinase is composed of three subunits:  
alpha, beta, gamma. The alpha subunit is the site of phosphorylation (Thr 172) that 
occurs to activate the AMPK complex. This subunit can only be phosphorylated if the 
complex has been allosterically activated, that occurs on the gamma subunit.  
The beta subunit of the complex contains  a glycogen binding site, and is thought to be 
the subunit that holds the other two subunits together.  The gamma subunit contains two 
Bateman domains which is where AMP binds [6]. 
AMP‘s binding to the gamma subunit allosterically promotes the phosphorylation of the 
complex at the alpha subunit by an upstream kinase: those that have been recently 
identified are:  a complex between the tumor suppressor protein LKB1 and accessory 
subunits termed STRAD and MO25 [7] and CAMKKbeta, found to be the upstream 
kinase in the brain, thymus, T cells, and tumor cells. Apart from promoting 
phosphorylation AMP binding also makes the AMPK complex a worse substrate for 
protein phophateses that dephosphorylate the alpha subunit (Thr 172). (Figure 1) 
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Biochemical studies from the end of last century were showing that gene 
encoding for Adenosine mono-phosphate protein kinase was present in all eukaryotic 
species,  vertebrates and invertebrates [8] Following, this same gene coding was found 
to be present and involved in the yeast Saccarhomcyes Cervisiae response to glucose 
starvation [9] as well as during the darkness period of green plants, when without the 
sun, therefore lack of photosynthesis, are unable to produce glucose.  AMPK, a trimmer 
with two AMP binding sites, has been termed as the cell‘s ―energy gage‖, sensing any 
slight change increase in cellular AMP, causes an immediate activation of various 
cascades mechanism: activation of energy producing pathways, and blocking energy 
depletion pathways (protein synthesis). (Figure 2).  
 
 
 
Figure 1 
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After the discovery of AMPK‘s key role in the muscular adaptations that occur 
following exercise [10], research began to unfold in the cardiovascular field, and is now 
recognized as playing a critical physiological role in the cardiovascular system. 
Increasing evidence suggest that AMPK might also function as a sensor by responding 
to oxidative stress. Mostly importantly, AMPK modulates endogenous antioxidant gene 
expression and/or suppress the production of oxidants. AMPK promotes cardiovascular 
homeostasis by ensuring an optimum redox balance on the heart and vascular tissues. 
Dysfunctional AMPK is thought to underlie several cardiovascular pathologies [11].  
Sirtuin 1 
Sirt1 is the human homolog of Sir2, part of the family of NAD+ dependent deacetylase.   
Its discover y in 2000 by Leonard Guarente fist demonstrated that Sir2 controlled the 
longevity of yeast, which following lead to a hype in research exploring this area in 
search for the human homolog [12].  To the pleasant surprise of many, the human 
homolog of Sir2, Sirt1, has revealed to have more positive effects than expected, aside 
from effecting the longevity of an organism, it plays a critical role in the regulation of 
Figure 2 
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metabolism in response to changes in nutritional availability in multiple tissues. (Figure 
3). [13]. 
 
  
 
 
 
 
 
 
SIRT1 is located in the nucleus of a cell. It activates downstream pathways by 
deacetylating its target proteins‘ lysine and placing the acetyl on the NAD molecule, to 
then form 2-o acetyl ADP ribose and nicotinamide(Fig 4) , the substrate then used in 
NAD+ biosynthesis  (Fig 5) . [14]. 
 
 
 
 
\ 
 
  
 
SIRT1 is said to receive its metabolic status information via NAD availability. NAD is 
found in the nucleus as the reducer, proton donor, NADH, a crucial part of cellular 
Figure 5 Figure 4 
Figure 3 
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metabolism: glycolysis, citric acid cycle, and oxidation phosphorylation.   As the rate of 
metabolism increases, there is an increase in the presence of NAD+  and the ratio 
NAD+/NADH increases.  The increase in NAD+ availability not only activates SIRT1, 
but its presence alone allows for it to deacetylate a downstream protein.  SIRT1 can 
deacetylate both acetylated histone proteins, including acetylated histone residues 
H3K56 [15], H4K16, and H3K9 [16,17], and non-histone targets such as p53, FOXO-
family transcription factors, and PGC-1a [18, 19, 20]. 
 It has been recently demonstrated that only after 4 days of high intensity interval 
training in humans not only increases mitochondrial biogenesis (well-known), but also 
that the increase in biogenesis is also coupled with an increase PGC-1alpha protein and 
increase SIRT1 activity but a decrease in SIRT1 protein [21].  When comparing aging 
effects with exercise effects in mice heart, it was concluded that exercise training, which 
significantly increases SIRT1 activity, could counteract age-related systems impairment. 
[22].  
Adiponectin 
Adiponectin is a 247-amino acid peptide with a collagenous domain at the n-terminus 
and a globular domain that shares substantial homology with the subunits of 
complement factor C1q [23]. Adiponectin is mainly secreted from adipose tissue, in 
humans, however, its expression was also found in bone marrow, osteoblasts, fetal 
tissue, myocytes, cardiomyocytes and salivary gland epithelial cells [23]. What makes 
adiponectin a particularly interesting adipokine is that population studies show that 
while the majority of secreted hormones increase as fat mass increases, adiponectin, on 
the other hand in inversely related with fat mass, more specifically with visceral fat,  
and its decrease is independently associated  to the metabolic syndrome [24,25]. It has 
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been found that adiponectin inhibits monocyte adhesion to endothelial cells , 
macrophage transformation to foam cells , and vascular smooth muscle cell proliferation  
in vitro. In vivo, forced adiponectin expression reduces atherosclerotic lesions in a 
mouse model of atherosclerosis , whereas adiponectin-deficient mice exhibit excessive 
vascular remodeling response to acute injury and diet-induced insulin resistance. 
Therefore, adiponectin has gained considerable attention because of its antidiabetic, 
antiatherogenic and anti-inflammatory properties [26].   
The discovery of the adiponectin receptors (AdipoR1, AdipoR2 and T-cadherin) 
as well as their extensive distribution in peripheral tissues and organs further suggests 
that adiponectin exerts pleiotropic effects on whole-body metabolism [23] (Figure 6). 
Both receptors  have homology to G-protein coupled receptors, and both effect the 
downstream kinase of AMPK, however mouse knockout studies linked AdipoR1 more 
closely to the activation of the AMPK pathway, whereas AdipoR2 is more tightly 
involved in the PPARα pathway.  
The regulation of adiponectin expression has yet to be fully determined. 
Analysis of the promoter region of the human adiponectin gene revealed several 
regulatory elements. Recent  studies show that SIRT1 can up-regulate adiponectin gene 
expression by enhancing the formation of a FOXO1-C/EBPα transcription complex, 
which is recruited to the adiponectin promoter [23].  
In relation to physical activity it was demonstrated that in humans, vigorous 
exercise increased serum adiponectin when compared to their sedentary counterparts 
independent of weight [27].  Not only is serum adiponectin increased but also 
adiponectin receptors increases following training in skeletal muscle [28].  
 
 11 
 
 
 
 
 
 
 
 
 
 
 
Following are presented three scientific articles that have been published 
resulting  from last three years of doctoral research, each one having to do with a 
different aspect of the proteins described above. 
Figure 6 
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CHAPTER 1: UPREGULATION OF SIRT1 DEACETYLASE IN 
PHENYLEPHRINE-TREATED CARDIOMYOBLASTS 
 
INTRODUCTION 
 
Disparate mechanisms of cardiac stress invoke a common pathway of adaptive 
myocyte hypertrophy which progresses into impaired systolic function and dilated, 
thinned myocardium, and finally heart failure, which is presently the leading cause of 
hospitalization and death in developed countries [1].  Recently, members of the sirtuin 
family, specifically SIRT1, have become a focus in cardiovascular research [2,3]. 
SIRT1 is an ubiquitous, nuclear and cytoplasmic NAD+ dependent deacetylase that 
deacetylates both acetylated histone and non-histone targets [4]. SIRT1, thought to be 
implicated in the control of longevity and aging, has an important role in metabolic 
regulation and receives its metabolic status information via NAD+ availability [2]. 
Various studies have shown SIRT1 activation as protective against cellular stress. In 
cardiac cellular models, SIRT1 has been found to be protective against hypertrophic, 
oxidative, and metabolic stress resulting in increased cell survival [5-9]. The link 
between SIRT1 and cardiac hypertrophy is however complex and not fully understood. 
In the whole animal, cardiac hypertrophy is associated with increased SIRT1 expression 
[5,10,11] whereas, on the other hand, SIRT1 overexpression or activation by resveratrol 
results in the inhibition of hypertrophy [12, 13]. Different effects can also be obtained 
depending on the extent of SIRT1 overexpression [3,14] 
Another protein involved in the response to cellular stress is AMP-activated 
protein kinase (AMPK), a key enzyme that regulates cellular energy state, growth, and 
many other cellular functions [15]. Analogous to SIRT1, the role of AMPK in cardiac 
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hypertrophy is complex, but it is however acknowledged that AMPK has an anti-
hypertrophic role, because when activated it inhibits ATP consuming pathways such as 
protein synthesis [16]. Being both, SIRT1 and AMPK, enzymes that regulate 
metabolism, it was not surprising to see that SIRT1 can activate AMPK, whereas 
AMPK in turn can activate SIRT1 [17]. Since both SIRT1 and AMPK are implicated as 
being protective against cardiac hypertrophy and have been suggested as pharmaceutical 
targets [18,19], understanding their response under hypertrophic stress is of importance. 
With this in aim, we have studied in H9c2 cardiac myoblasts, the response of SIRT1 to 
phenylephrine, recognized to induce a hypertrophic process in this cardiac cell model 
[20,21].    
 MATERIALS AND METHODS 
Cell culture and treatment 
H9c2 cardiomyoblasts (embryonic rat heart derived cells) were cultured in Dulbecco's 
modified Eagle's medium (DMEM, Celbio) supplemented with 10% heat inactivated 
fetal calf serum (FCS), 5% glutamine and antibiotics. Before the treatments, the cells 
were serum starved for 18 h in medium containing 1% FCS. All tested compounds were 
dissolved in phosphate-buffered saline (PBS) or DMSO at a 1000x concentration. 
Control cells received the corresponding volume of the vehicle. 
Cell viability was determined by trypan blue exclusion. Samples were done in triplicate, 
and at least 10 fields were counted for each sample.  Cell survival was calculated as the 
percentage of living viable cells in treated samples in respect to the number of viable 
cells in control samples.  
 
Western Blotting 
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H9c2 cells were collected in lysis buffer (5 mM dithiothreitol, 2 mM EDTA, 0.1% 
CHAPS, 0.1% Triton X-100, and protease inhibitors in 20 mM HEPES pH 7.5) and 
subjected to two cycles of freeze-thawing. The homogenate was then centrifuged at 
15,000 × g for 15 min and the supernatant, diluted in loading buffer (2% SDS, 5% 
glycerol, 0.002% bromophenol blue, 4% β-mercaptoethanol in 0.25 M Tris–HCl, pH 
6.8) and boiled for 4 min. Aliquots corresponding to 120 μg protein were analyzed by 
SDS-PAGE and immunoblotting. Immunoreactive bands were visualized by 
chemioluminescence with the ECL reagent (Amersham). Anti-SIRT1 and anti β-actin 
were obtained from Santa Cruz.  Antibodies against phospho-Acetyl Coenzyme A 
Carboxylase β (ACC) (Ser79), AMPKα1/α2 and phospho-AMPKα1/α2 (Thr172) were 
from Cell Signaling. β-Actin was used as internal control.  Quantitative assay of blots 
was obtained by densitometry with a Fluor-S Max Multilmager (Bio-Rad). 
 
SIRT1 activity  
The enzymatic deacetylase activity of SIRT1 was assayed using an immune-complex 
fluorometric 
assay. SIRT1 was  immunoprecipitated  from H9c2 soluble extracts (0.5 mg of protein) 
[22], and the final SIRT1-immune-complex was resuspended in 0.16 ml of assay buffer 
(5 mM dithiothreitol, 0.1 M NaCl, 0.1% Triton X-100, 20% glycerol, 20 mM Tris/HCl 
pH 7.6). The sample divided into four 40 l aliquots that were separately assayed (in 
presence or absence of NAD
+
) in a final volume of 50 l containing  100 M NAD+  
and 100 M of the acetylated tetrapeptide  RHKKAc–AMC [23] purchased from 
LifeTein, South Plainfield, NJ. This peptide is based on the amino acid sequence of 
human p53 close to Lys382. The reaction was  incubated for 90 min at 37°C, afterward 
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50 l of stop solution (40 mM nicotinamide, 10 mg/ml  trypsin, 0.2 M NaCl  in   0.1 M 
Tris pH 8) were added. After further 20 min at 37 °C, 2.5 ml of water were added to 
each tube and fluorescence was read in a Perkin Elmer fluorescence spectrometer (ex 
370, em 450). SIRT1 activity was calculated from the fluorescence developed in the 
complete assay, after subtraction of the fluorescence measured in absence of NAD
+
. 
Preliminary experiments to optimize assay linearity and to calculate the recovery of 
SIRT1 activity  in the whole procedure, were done  by adding to extracts a known 
amount of recombinant SIRT1 protein (Sigma-Aldrich). 
 
Cell metabolites 
Acid-soluble metabolites were extracted in ice cold 0, 3M perchloric acid and measured 
by HPLC after extract neutralization with buffered 3M KOH. The cellular content of 
ATP and other nucleotides was determined  after conversion into fluorescent etheno-
derivatives [24]. NAD
+
 and NADH were directly determined in the neutralized extract 
by detection at 260 nm after separation [25]. 
  
 RNA interference  
The sequences of siRNAs directed against rat SIRT1 and the catalytic subunits of 
AMPK (Obtained from Sigma-Genosys) were as follows: for SIRT1, 5'-
CACCUGAGUUGGAUGAUAU-3'; for AMPKα1, 5'-
CUUAUUGGAUUUCCGAAGUTT-3';
 for AMPKα2, 5'-
GACAUUAUGGCGGAGGUGUTT-3'. Control siRNA-A was purchased
 
from Santa 
Cruz Biotechnology.  Cells at 50 % of confluence were transfected with a final 
concentration of 100 nM siRNA duplex for 24 h by Transfection reagent (Santa Cruz) 
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according to manufacturer‘s instructions. 24 hours after transfection, cells were then 
treated with the designated drugs. 
 
 Data analysis 
All the experiments shown were performed independently at least three times with 
comparable results. The blots are representative of results obtained in multiple 
experiments. All the data presented in graphs are expressed as means ± S.E. of the mean 
of the indicated numbers of determinations. Comparison between two groups were done 
by Student‘s unpaired two-tailed t test. Differences were considered as significant when 
P < 0.05. 
 RESULTS 
H9c2 heart cells represent a useful model in which molecular event associated to 
hypertrophy can be studied [26]. In these cells, the adrenergic effector phenylephrine 
causes a hypertrophic response similar to that evoked in primary cardiomyocytes and in 
the whole heart [20,21]. Since sirtuins are associated to the cell stress response, the 
hypothesis that phenylephrine could influence SIRT1 was tested. Analysis of soluble 
extracts prepared from whole H9c2 cell lysates showed increased SIRT1 protein levels 
in cells treated with 10 g/ml phenylephrine for 24-48 h with respect to control cells 
(Fig. 1A).  The increase of SIRT1 at 24 h observed in several independent experiments 
ranged from 1.6 to 3.5 times as determined by densitometric analysis of bands obtained 
by Western blotting. Fig. 1B shows that even the deacetylase activity of SIRT1 in 
soluble extracts was significantly increased following 24 h of treatments with 
phenylephrine. This activity was defined as the enzymatic activity immunoprecipitable 
by SIRT1 monoclonal antibody that deacetylates an acetylated-peptide substrate  in the 
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presence of NAD
+
. The content of SIRT1 protein was also increased by the 
physiological  adrenergic effector norepinephrine (10 µg/ml), whereas pretreatment 
with the non-specific alpha-receptor  antagonist phentolamine partially inhibited the 
phenylephrine-induced increase in SIRT1 expression (Fig. 1C). 
Interestingly, it has been reported that phenylephrine rapidly stimulates the 
phosphorylation of the catalytic α-subunit of AMPK within a few minutes in H9c2 cells 
[27]. The experiment depicted in Fig. 2A confirms an increase in AMPK- (Thr172)  
phosphorylation following treatment with phenylephrine (10 g/ml), and shows that this 
is not a strictly transient event, being detectable 1h and 2 h after the treatment. To 
determine whether AMPK activity was linked to the augmented expression of SIRT1, a 
pharmacological approach was firstly used (Fig. 2B).  When H9c2 cardiomyoblasts 
were exposed for 24 hours to phenylephrine in the presence of AMPK inhibitors AraA 
(0.5 mM) [28]  or STO-609 (1µM) [29], the increase in SIRT1 levels was not evident. 
On the other hand, the AMPK activator AICAR (4 mM) significantly increased the 
effect of phenylephrine on SIRT1 level. The effects of the aforementioned AMPK 
modulators on SIRT1 was very similar to that caused on the phosphorylation of ACC 
(Ser79), a physiological substrate of AMPK, suggesting an association between AMPK 
activity and SIRT upregulation by phenylephrine. To support this suggestion, a siRNA 
approach was used.  The cells were treated with two siRNAs respectively targeted 
against the α1 and α2 catalytic subunits of AMPK in order to knockdown AMPK 
activity, or with a control siRNA of random sequence without any target- The 
cardiomyoblasts were then exposed for 24 hours to phenylephrine. Fig. 2C shows that 
inhibition of AMPKα1/α2 expression by siRNA caused a significant degree of reduction 
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in SIRT1 content in phenylephrine-treated cells. Taken together, these results strongly 
suggest that upregulation of SIRT1 by phenylephrine depends on AMPK activity.  
The sensing of cellular metabolic stress by AMPK and SIRT1 is mediated through 
changes in the levels of adenine nucleotide and NAD
+
 respectively. However, we were 
not able to detect any significant change in the cellular content of AMP, ADP, ATP, 
NADH and NAD
+
 in cells treated with phenylephrine for 1, 4 or 24 hours with respect 
to control cells (data not shown).  
In order to evaluate whether MAPK or Akt pathways, associated to adrenergic 
stimulation of heart cells, could be involved together with AMPK in SIRT1 activation, 
we tested the effect of pharmacologic inhibitors in phenylephrine-treated H9c2 cells. 
The inhibitors of the MAPK cascade U0126 (10 µM) and PD98059 (50 µM) were 
without any effect, whereas the PI3K/Akt pathway inhibitor LY294002 (20 µM) 
reduced SIRT1 activation (Fig. 2D).  
In order to define whether SIRT1 could exert a protective effect in H9c2 cells exposed 
to hypertrophic stress, the cells were incubated 72 h with increasing doses of 
phenylephrine in the presence of the SIRT1 inhibitor sirtinol (20 µM). Fig. 3A shows 
that at the used concentration, sirtinol did not elicit toxic effect in untreated cells. On the 
other hand, when SIRT1 was inhibited by sirtinol in phenylephrine-treated cells, the cell 
survival was significantly decreased, suggesting a protective action of SIRT1 in stressed 
cells. To confirm this suggestion, SIRT1 expression was knocked-down by siRNA. The 
levels of SIRT1 was significantly decreased in cells treated with SIRT1-siRNA, 
compared to untreated cells and to cells treated with control siRNA (Fig. 3B). In control 
cells, treatment with either control siRNA or SIRT1-siRNA caused a similar decrease of 
viability, probably caused by unspecific toxicity of the transfection procedure.  
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Conversely, when the cardiomyoblasts were exposed to phenylephrine, cell death was 
largely increased in SIRT1 knocked-down cells, where cell survival was reduced to less 
than 50%, a value significantly lower with respect to that determined in cells pretreated 
with control siRNA. Altogether, these data indicate that SIRT1 is important to support 
survival in cardiomyoblasts treated with phenylephrine. 
DISCUSSION 
SIRT1 plays a role in biological processes such as longevity, apoptosis, and metabolic 
stress resistance by deacetylating histones H4 and H3 and other proteins including p53, 
Forkhead box transcription factors,  nuclear factor kappa B, and peroxisome proliferator 
activated gamma coactivator 1a [2-4]. Since their discovery, sirtuins have been linked 
with metabolic and cardiovascular  diseases, including heart hypertrophy [2,3]. SIRT1, 
the most studied sirtuin, was first investigated as the mechanism behind the increase in 
lifespan due to caloric restriction, but SIRT1 enzymatic activity has also been linked to 
the known beneficial adaptations seen with aerobic physical activity [30] that represent 
a valid treatment for metabolic and cardiovascular diseases [31]. Results from this study 
can suggest that the adaptive signaling leading to SIRT1 upregulation that occurs during 
exercise (including physiological cardiac hypertrophy) or during the development of 
pathological cardiac hypertrophy can also be in response to the increase in adrenergic 
stimulation.  
We have shown that adrenergic stimulation causes an increase in SIRT1 protein and 
activity in cardiomyoblasts, that is protective against the cell damage associated to 
hypertrophic stress. This finding is consistent with previous reports showing that SIRT1 
upregulation by overexpression or resveratrol results in heart cell cytoprotection against 
oxidative and hypertrophic stresses [5,7,9]. Our study however, shows that the same 
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trigger of the hypertrophic signaling causes SIRT1 upregulation,  coherently with the 
increased SIRT1 expression observed in some models of cardiac hypertrophy [10,11].  
On the other hand, SIRT1 can also inhibit the development of hypertrophy [12,13],  
suggesting that phenylephrine activates simultaneously both hypertrophic programming 
and a self-protecting/self-regulating mechanism. 
Our results also imply that the signaling axis leading to SIRT1 induction involves 
AMPK.  Adrenergic agonists activate AMPK in several cells and tissues, including 
different cardiac models  [27,32-34]. Regarding H9c2 cells, Xu and coworkers [27] 
reported a rapid increase in AMPKα Thr172 phosphorylation in response to 
phenylephrine. Recently, Pang et al. [35] reported that Ser485/491 is the main site of rat 
heart AMPK phosphorylation in response to phenylephrine. In our hands, phenylephrine 
stimulated H9c2 AMPKα phosphorylation detected by means of an antibody directed 
against phospho-Thr172. This effect could be seen for a few hours from the treatment 
and was associated to increased enzyme activity, as shown by the elevation in ACC 
phosphorylation. However, the basal degree of AMPKα (Thr172) and ACC (Ser79) 
phosphorylation in control cells indicate a constitutive basal level of AMPK activity, 
hence the exact role of AMPK activation and of AMPK phosphorylation site on SIRT1 
activation remains to be defined, since our data only show that the presence of an active 
AMPK is required for SIRT1 upregulation. 
Other studies have reported that SIRT1 activity can be mediated by AMPK  [36,37]. In 
these studies AMPK activation was achieved by glucose restriction or pharmacological 
activation (AICAR, metformin, or dinitrophenol) and  was associated  with the increase 
in NAD
+
/NADH ratio. We were unable to detect any changes in NAD+, NADH, ATP, 
ADP, AMP concentrations, suggesting that adrenergic stimulation upregulates Sirt1 via 
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a metabolism-independent pathway; even so, AMPK seems to play an important 
mediating role. On the other hand, additional signaling pathways are probably involved 
in SIRT1 activation in response to phenylephrine. The kinase Akt is an interesting 
candidate, since it is activated in response to phenylephrine [38,439] and can lead to 
induction of proteins associated with cell survival, including SIRT1 [40]. Furthermore, 
Akt activity can be increased upon AMPK activation that inhibits mTOR, a downstream 
targets of Akt, so then preventing feedback inhibition of PI3K and Akt  [41,42]. 
Interestingly, during cardiomyocyte response to oxidative stress, AMPK and Akt 
collaborate to activate GLUT4 translocation [43]. We have observed that SIRT1 
upregulation by phenylephrine is abrogated by the PI3K inhibitor LY294002, 
supporting a role of  Akt in SIRT1 regulation. Following experiments will investigate 
the role of Ca
++
-activated pathways in the effect of phenylephrine on SIRT1, since 
IP3/Ca
++
 signaling leads to Akt activation, whereas the Ca
++
/CaM/CaMKK axis may 
activate AMPK. 
In conclusion, a chronic exposure of H9c2 cardiomyoblasts to the α-adrenergic 
agonist phenylephrine caused an increase in SIRT1 protein expression along with its 
activity.  SIRT1 upregulation required AMPK activity and promoted cell survival. We 
so then propose that the increase in SIRT1 activity and expression is an adaptive 
response to hypertrophic stress, suggesting that adrenergic stimulation of heart cells 
along with the hypertrophic programming also promotes self-protecting and self-
regulating mechanisms. 
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Fig.1. SIRT1 is upregulated by phenylephrine in H9c2 cardiomyoblasts. (A) The cells 
were incubated in the absence or presence of 10 µM phenylephrine for the indicated 
time. The content of SIRT1 was then determined in cell lysates by Western blotting.  
(B) The deacetylase activity of SIRT1 was measured in extracts obtained from control 
cells and from cells incubated 24 h with 20 µM resveratrol or 10 µM phenylephrine. 
Results are means ± SE of four determinations. *, P < 0.05 vs. control cells. (C) The 
content of SIRT1 protein was determined in lysates from cells incubated 24 h in the 
presence of the indicated concentration of norepinephrine (NE) or phenylephrine (PE). 
Phentolamine (PA) concentration was 10 µM. 
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Fig. 2.  AMPK involvement in SIRT1 upregulation by phenylephrine in H9c2 
cardiomyoblasts.  (A) The cells were incubated in the absence or presence of 10 µM 
phenylephrine for the indicated time. To assay phosphorylation and amount of AMPK, 
cell lysates were analysed by Western blotting with antibodies against α subunits of 
AMPK (AMPKα) or Thr172-phosphorylated α subunits of AMPK (P-AMPKα). (B) The 
cells were incubated for 24 h in the absence or presence of 10 µM phenylephrine and 
the indicated compounds: AraA (0.5 mM), STO-609 (1µM), AICAR (4 mM). The 
content of SIRT1 and phospho-ACC (Ser79) were assayed in cell lysates by Western 
blotting. (C) The amount of SIRT1 and AMPKα were determined in cell extracts 
obtained from cells incubated for 24 h in the absence or presence of 10 µM 
phenylephrine after transfection with AMPKα1 plus AMPKα2 siRNAs (AMPK siRNA) 
or control siRNA. 
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Fig. 3. SIRT1 promotes cell survival of phenylephrine-treated H9c2 cardiomyoblasts. 
(A) Cell viability was measured following incubation for 72 h with the indicated 
concentration of phenylephrine in the absence or presence of 20 µM sirtinol. Results are 
means ± SE, n=3. (B) Untransfected cells and cells transfected with SIRT1 siRNA or 
unrelated control siRNA were incubated for 72 h in the absence or presence of 10 µM 
phenylephrine. The extent of cell death was then measured. Values are expressed as 
means ± SE of triplicate determinations, *, P < 0.05. The blots show the effect of 
siRNA transfection on SIRT1 expression and are representative of three experiments. 
 
 
 
 29 
CHAPTER 2: EVIDENCE THAT AMP-ACTIVATED PROTEIN 
KINASE CAN NEGATIVELY MODULATE ORNITHINE 
DECARBOXYLASE IN CARDIAC MYOBLASTS 
 
 INTRODUCTION 
 
Cardiac hypertrophy and subsequent progression to heart failure represents a 
major cause of morbidity and mortality in industrialized countries. The defining features 
of cardiac hypertrophy are an increase in cardiomyocyte size, enhanced protein 
synthesis, and a higher degree of sarcomere organization [1]. These changes are 
preceded and accompanied by the re-induction of the so-called fetal cardiac gene 
program, characterized by a pattern of altered gene expression that mimics that 
observed during embryonic heart development [2]. Cardiac hypertrophy is also 
associated with a shift from fatty acids to glucose as energy source, an additional feature 
in common with the fetal heart. 
A characteristic event in response to agents that induce cardiac hypertrophy is 
the upregulation of Ornithine decarboxylase (ODC), the key enzyme in polyamine 
biosynthesis. The correlation between polyamines and cardiac hypertrophy has been 
well established  [3] and all cardiac hypertrophy inducers cause an early induction of 
cardiac ODC in both whole animal [4-6] and cellular models [7-9]. In the classical 
model of adrenergic agonist-induced hypertrophy, pharmacological inhibition of ODC 
results in abrogation or attenuation of the hypertrophic response [5-7,10], indicating a 
key role of ODC in this process, as confirmed by the marked increased in sensitivity to 
isoproterenol-induced hypertrophy of  transgenic mice with targeted overexpression of 
ODC in the heart [11]. 
 30 
Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a  key 
metabolic regulator that  is activated  in response to metabolic stress (altered energy 
supply and/or demand). Additionally. this enzyme can be activated by hormones that 
influence cellular metabolism, such as adiponectin and catecholamines [12]. The role of 
AMPK in cardiac hypertrophy is complex, as demonstrated by  contrasting findings in 
literature. Many papers, reviewed in [13,14], have shown that  AMPK has an anti-
hypertrophic role. In this respect,  genetic models of diminished heart AMPK activity 
show an  enhanced cardiac hypertrophy [15,16] and AMPK  inhibits ATP consuming 
pathways such as protein synthesis [17]. On the other hand, activation of AMPK in 
hypertrophied hearts has been observed in a number of studies, reviewed in [14,18], and 
could be associated to the increase energetic requirements of hypertrophic heart [19-21]. 
Furthermore, adrenergic agonists , classic inducers of cardiac hypertrophy either in vivo 
and in vitro,  cause increased AMPK activation  in several cell lines and tissues, 
including different cardiac models  [22-25]. In this light, the typical ODC induction 
triggered by adrenergic agonists discussed above, seems to be in contrast with the well 
documented homeostatic role of AMPK that inhibits protein synthesis by interfering 
with the mTOR pathway [17, 26]. To date, nothing is known about the possible 
interrelation between AMPK and ODC. In the study presented below  we examined the 
adrenergic agonist response of these two enzymes in H9c2 heart cells, a useful model in 
which molecular events associated to hypertrophy can be studied [27]. 
 MATERIALS AND METHODS 
Cell culture and treatment 
H9c2 cardiomyoblasts (embryonic rat-heart derived cells) were cultured in 
Dulbecco's modified Eagle's medium (DMEM, Celbio) supplemented with 10% heat 
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inactivated fetal calf serum (FCS), 5% glutamine and antibiotics. Cardiomyocyte 
cultures were prepared from 1- to 3-day old neonatal Wistar rat hearts, as described 
previously [9]. Before the treatments, the cells were serum starved for 18 h in medium 
containing 1% FCS. All treatments were dissolved in phosphate-buffered saline (PBS) 
or DMSO at a 1000x concentration and added to cell cultures (0.1% with respect to the 
total volume) in order to obtain the required concentration in the medium. Control cells 
received the corresponding volume of the vehicle. Cell viability was determined by 
trypan blue exclusion by counting living cells and stained dead cells with a Burker 
hemocytometer.  
Western Blotting 
H9c2 cells were collected in lysis buffer (5 mM dithiothreitol, 2 mM EDTA, 
0.1% CHAPS, 0.1% Triton X-100, and protease inhibitors in 20 mM HEPES pH 7.5) 
and subjected to two cycles of freeze-thawing.  Rat hearts were homogenised in 4 vols 
of the same buffer by an  ultra Turrax device. The homogenate was then centrifuged at 
15,000 × g for 15 min and the supernatant, diluted in loading buffer (2% SDS, 5% 
glycerol, 0.002% bromophenol blue, 4% β-mercaptoethanol in 0.25 M Tris–HCl, pH 
6.8), and then denatured by boiling for 4 min. Aliquots corresponding to 130 μg protein 
were analyzed by SDS-PAGE. Proteins were transferred onto a nitrocellulose 
membrane and probed with the specific primary antibody. After further washing, the 
membrane was then incubated for 1h with peroxidase-conjugated goat anti-rabbit IgG 
(Santa Cruz). Immunoreactive bands were visualized by chemioluminescence with the 
ECL reagent (Amersham). Antibodies against phospho-Acetyl Coenzyme A 
Carboxylase β (ACC) (Ser79 in human), AMPKα1/α2 and phospho-AMPKα1/α2 
(Thr172 in human) were from Cell Signaling. Anti-Akt and anti β-actin were obtained 
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from Santa Cruz. β-Actin was used as an internal control.  Quantitative assay of 
immunoblotting was obtained by densitometry with a Fluor-S Max Multilmager 
instrument (Bio-Rad). 
ODC activity 
To measure the activity of  ODC, the cells were washed with PBS and scraped in 
a buffer consisting of 0.1 mM EDTA, 0.02 mM pyridoxal phosphate, 2.5 mM 
dithiothreitol in 10 mM sodium phosphate buffer, pH 7.2. The cells were disrupted by 3 
cycles of freeze-thawing and then centrifuged at 11,000 rpm for 15 min. ODC activity 
in the supernatant was measured in duplicate by estimating  the release of 14CO2 from 
[14C-Carboxyl]-ornithine during 60 min incubation [28].   Specific ODC activity is 
expressed as units/mg protein, where 1 unit corresponds to 1 pmol of CO2/min of 
incubation. The amount of protein in samples  was determined by Coomassie blue 
staining. 
Cell metabolites 
Acid-soluble metabolites were extracted in ice cold 0, 3M perchloric acid and 
measured by HPLC. Separations were achieved by a 25 cm x 4.6 mm Gemini 5µ 
column from Phenomenex. Polyamines were determined in acidic cellular extracts by 
reversed phase HPLC after derivatization with dansyl chloride [28]. The cellular content 
of ATP and other nucleotides was determined  after extract neutralization with buffered 
3M KOH following conversion into fluorescent etheno-derivatives [29].  
RNA interference  
 The sequences of siRNAs directed against the catalytic subunits of rat AMPK 
(Obtained from Sigma-Genosys) were as follows: for AMPKα1, 5'-
CUUAUUGGAUUUCCGAAGUTT-3'; for AMPKα2, 5'-
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GACAUUAUGGCGGAGGUGUTT-3'. In most experiments, a siRNA against 
Luciferase was used as negative control (5'-AACUUACGCUGAGUACUUCTT-3'). In 
some cases, the control siRNA-A, purchased from Santa Cruz Biotechnology, was used.  
Cells at 50 % of confluence were transfected with a final concentration of 100 nM 
siRNA for 24 h by Transfection reagent (Santa Cruz) according to manufacturer‘s 
instructions. 24 hours after transfection, cells were then treated with the designated 
drugs. 
Data analysis 
All the experiments shown were performed independently at least three times 
with comparable results. The blots are representative of results obtained in multiple 
experiments. All the data presented in graphs are expressed as means ± S.E. of the mean 
of the indicated numbers of independent determinations. Statistical comparison between 
two groups were done by Student‘s unpaired two-tailed t test. Differences were 
considered as significant when P < 0.05. 
RESULTS  
Adrenergic agonists such as phenylephrine and isoproterenol cause in H9c2 
cardiomyoblasts a hypertrophic response similar to that evoked in primary 
cardiomyocytes and in the whole heart [30-32]. First, the effect of isoproterenol on 
AMPK activation was  studied. Analysis of soluble extracts prepared from whole H9c2 
cell lysates showed increased AMPK- (Thr172)  phosphorylation following treatment 
with isoproterenol (10 g/ml). The experiment depicted in Fig. 2A shows that an 
increased phosphorylation of AMPK α catalytic subunits could be observed as soon as 
15 min. This effect remained detectable for 2-3 h and was not associated to any changes 
in the level of ATP, ADP and AMP, that were unchanged (not shown). AMPK 
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phosphorylation was also increased (Fig. 2B) in response to phenylephrine and the 
physiological effector, norepinephrine (both 10 µg/ml), as per previous reports [23,33]. 
Treatment with isoproterenol increased ODC activity in H9c2 cells with a timing 
identical to that observed in rat cardiomyocytes [7] and in the whole heart [4]. The 
increase in enzyme activity was very rapid and became significant between 15 and 30 
min after  treatment (Fig. 2A). After 4 h of treatment, putrescine, the product of ODC 
catalysis, was increased (Fig. 2B), whereas the major polyamines spermidine and 
spermine were unchanged (not shown). The increase in ODC activity was blocked by 
cycloheximide, an inhibitor of protein synthesis (Fig. 2C). ODC is a short-lived protein, 
whose level can be regulated by the rate of its proteasomal degradation [34]. In the 
presence of the proteasome inhibitor MG132, basal ODC activity was increased as 
expected, however, isoproterenol continued to increase ODC activity (Fig. 2D), 
indicating that change in protein stability was not involved in the response to 
isoproterenol. These data show that isoproterenol induced ODC activity by increasing 
the synthesis of new enzyme protein, accordingly to the most common mechanism of 
ODC regulation [34].   
In order to evaluate the putative signal transduction pathways involved in ODC 
induction in isoproterenol-treated H9c2 cells, we tested the effect of some 
pharmacological inhibitors. Table 1 shows that  PD98059 (50 µM), inhibitor of the 
MAPK cascade, H89, a PKA inhibitor, and KN93, a CAMK-II inhibitor, were without 
any significant effect.  On the contrary, ODC induction by isoproterenol was abolished 
in cells treated with the PI3K/Akt pathway inhibitor Wortmannin or with the dual 
PI3K/mTOR inhibitor BEZ235, suggesting a central role of Akt-mediated signal in the 
ODC response to isoproterenol. To determine whether the observed AMPK activation 
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could influence the response of ODC, H9c2 cardiomyoblasts were exposed for 2 hours 
to isoproterenol in the presence of AMPK inhibitors AraA [35] or STO-609. This last 
compound is a CAMKKβ inhibitor, a proven powerful direct inhibitor of AMPK  [36]. 
Interestingly, ODC activity resulted slightly increased in cells incubated in the presence 
of either AraA or STO-609. On the contrary, the AMPK activator AICAR (4 mM) and 
expecially metformin (5 mM) slightly decreased ODC activity.  Phenformin, a more 
potent analogue of metformin, caused a dose dependent inhibition of ODC activity. 
These late results suggest that AMPK activity could be associated to decreased ODC 
activity.  On the contrary, ODC inhibition with 0,1 mM α-difluoromethylornithine 
(DFMO)  did not induce any effect on AMPK level or phosphorylation in either control 
cells or  isoproterenol-treated cells (not shown).  
Since the specificity of pharmacological inhibitors/activators always remains 
limited, to support the suggestion of a modulating effect of AMPK on ODC, a siRNA 
approach was used.  The cells were treated with two siRNAs respectively targeted 
against the α1 and α2 isoforms of the AMPK catalytic subunit in order to knock down 
AMPK enzymatic activity, or with a siRNA directed against luciferase (control siRNA). 
The cardiac myoblasts were then exposed for 2 hours to isoproterenol.  Fig. 3A shows 
that a significant degree of reduction in AMPKα level was obtained in cells pretreated 
with both siRNAs against α1 and α2 isoforms of AMPKα, that lead to a significant 
reduction in cellular AMPK activity, as shown by the decrease in the phosphorylation of 
ACC (Ser79), a physiological AMPK substrate. The knock-down of only one isoform of 
AMPKα did not influence ACC (Ser79) phosphorylation.  
When both  1 and  2 isoforms of AMPK were silenced, there was a marked 
increase in ODC activity in H9c2 cells treated with isoproterenol, along with the 
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decrement in AMPK activity. siRNA-mediated downregulation of a single isoform 
resulted to have a weaker effect on ODC activity, but the effect of the siRNA against  
α2 isoform was more pronounced when compared to the α1 isoform. Pretreatment with 
α1 plus α2 siRNAs also increased ODC activity in response to norepinephrine and 
phenylephrine (Fig. 3B). Fig. 3C depicts that the treatment with α1 plus α2 siRNAs did 
not influence the expression of ERK 1/2 or Akt, that are often associated to the growth 
promoting effect of adrenergic stimulation of cardiac cells [37,38]. 
DISCUSSION 
AMPK, that is allosterically activated by AMP and phosphorylated by upstream 
kinases, represents the link between cell growth and energy availability [12-14]. It is 
generally assumed that AMPK activates mechanisms that favor the formation of ATP 
both directly and indirectly, and contrastingly blocks mechanism that consume ATP, 
such as protein synthesis [17].  Because of it homeostatic role, AMPK could essential 
contrast  the hyperplastic as well as hypertrophic growth.  The heart can sustain two 
types of hypertrophic growth, one termed physiological hypertrophy also known as the 
athletic heart, that is reversible  once the cardiovascular stress ceases.  The second type 
of hypertrophy is termed systolic pathological, it is the outcome of the body‘s effort to 
adapt to an increase in afterload usually due to an increase in blood pressure and or 
valvular insufficiency. This particular type of hypertrophy is not reversible, and 
eventually leads to cardiac dilation ,and then finally congestive heart failure [1].  
Interest in defining AMPK‘s exact role in protein synthesis and therefore hypertrophy in 
cardiac cells lays in the hope of finding a key to pathological hypertrophy.  To evaluate 
the role of AMPK in cardiac hypertrophy, we have studied  the response of AMPK in   
in a cell model of induced hypertrophy represented by H9c2 cardiomyoblasts treated 
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with isoproterenol.    
Our findings demonstrated that treatment with adrenergic agonists, such as 
isoproterenol, quickly activates in cardiac cells two  mechanisms that seem to contrast 
one another. The first one, increase in ODC activity, is linked to cell growth, whereas 
the second, AMPK activation, is a homeostatic mechanism that negatively modulates 
the   first.  
ODC is the enzyme responsible for the biosynthesis of polyamines, that are 
known to be critical in the cell cycle, showing a marked increase during all cellular 
growth processes [39], and have a role in the development of cardiac hypertrophy [3-8]. 
We have shown that isoproterenol induces ODC activity in H9c2 cells, exactly like in 
other cardiac models, by promoting the synthesis of the enzyme. ODC is one of the 
most finely regulated enzyme [34] and its synthesis is modulated by the mTOR-p70s6K 
pathway [40], that is activated by isoproterenol in cardiomyocytes [41]. Actually, 
inhibition of the PI3K/Akt pathway, that leads to mTOR activation, blocked ODC 
induction by isoproterenol. Inhibition of mTOR represents the main mechanism of the 
anti-hypertrophic effect of AMPK [12,17]  and is probably also the mechanism 
responsible for the negative modulation of ODC.  
The question is why two apparently contrasting mechanisms are activated at the 
same time in heart cells committed to hypertrophy. We suspect that AMPK plays a 
regulatory role in the transition towards the hypertrophic phenotype. The rapid 
activation of AMPK following adrenergic stimuli is probably due to the cells effort to 
guarantee itself energetic substrates in order to respond to an increase in ATP demand.  
The lack of optimal nutritional conditions (energetic substrates) due to a prolonged 
activation of AMPK could instead contrast  the establishment of hypertrophy, possibly 
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also by means of the negative modulation of ODC activity.   
We have recently provided data suggesting that adrenergic stimulation of heart 
cells along with the hypertrophic program also promotes self-protecting and self-
regulating mechanisms [33]. The modulation of ODC activity by AMPK fits well in this 
model, since it could represent a powerful self-regulatory mechanism, that may 
represent a target for the pharmacological control of heart hypertrophy. 
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TABLES AND FIGURES 
Table 1. Effect of pharmacologic protein kinase inhibitor/activator on ODC activity in 
untreated and isoproterenol-treated H9c2 cardiomyoblasts.   
Treatment Addition Effect Target ODC activity 
(U/mg) 
-   (ctrl)    13 ± 3 
ISO    34 ± 6  
- Wortmannin (2 µM) inhibitor PI3K 8 ± 2 
ISO Wortmannin (2 µM) inhibitor PI3K 9 ± 2 
- BEZ235 (0.2 µM) inhibitor PI3K/mTOR 7 ± 3 
ISO BEZ235 (0.2 µM) inhibitor PI3K/mTOR 6 ± 2 
- PD 98059 (50 µM) inhibitor ERK1/2 13 ± 2 
ISO PD 98059 (50 µM) inhibitor ERK1/2 37 ± 4 
- H89 (5 µM) inhibitor PKA 15 ± 2 
ISO H89 (5 µM) inhibitor PKA 37 ± 4 
- KN93 (2 µM) inhibitor CAMKII 12 ± 3 
ISO KN93 (2 µM) inhibitor CAMKII 32 ± 5 
- STO 609 (1µM) inhibitor CAMKKβ/AMPK 16 ± 3 
ISO STO 609 (1µM) inhibitor CAMKKβ/AMPK 40 ± 4 
- AraA (0.5 mM) inhibitor AMPK 16 ± 2 
ISO AraA (0.5 mM) inhibitor AMPK 41 ± 5 
- AICAR (4 mM) activator AMPK 11 ± 3 
ISO AICAR (4 mM) activator AMPK 29 ± 4 
- Metphormin (5 mM) activator AMPK 9 ± 2 
ISO Metphormin (5 mM) activator AMPK 23 ± 4 
- Phenformin (0.5 mM) activator AMPK 12 ± 2 
ISO Phenformin (0.5 mM) activator AMPK 30 ± 4 
- Phenformin (1 mM) activator AMPK 9 ± 2 
ISO Phenformin (1 mM) activator AMPK 26 ± 3 
- Phenformin (2 mM) activator AMPK 8 ± 1 
ISO Phenformin (2 mM) activator AMPK 21 ± 3 
 
ODC activity was determined in extracts from cells incubated 2 h in the absence or 
presence of 10 µM isoproterenol (ISO) and the indicated compounds. Results are means 
± s.e.m. of triplicate determinations. 
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Figure 1.  AMPK phosphorylation is increased by isoproterenol in H9c2 
cardiomyoblasts.  (A) The cells were incubated in the absence or presence of 10 µM 
isoproterenol for the indicated time. Cell lysates were analysed by Western blotting with 
antibodies against α subunits of AMPK (AMPKα) or Thr172-phosphorylated α subunits 
of AMPK (P-AMPKα), or phospho-ACC (Ser79). (B) The cells were incubated for 1 h 
in the absence or presence of 10 µM Norepinephrine (NE), or  isoproterenol (ISO), or 
phenylephrine (PE), then cell extracts were analyzed by Western blotting. 
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Figure 2.  ODC activity is increased by isoproterenol in H9c2 cardiomyoblasts.  (A) 
The cells were incubated in the absence (empty symbols) or presence (black symbols) 
of 10 µM isoproterenol for the indicated time. Cell lysates were then assayed for ODC 
activity. (B) The content of putrescine was measured by HPLC in acid extracts from 
cells incubated for 4 h in the absence or presence of 10 µM isoproterenol (ISO). (C) 
H9c2 cells were treated with 10 µM isoproterenol  in the absence or presence of 0.2 mM 
cycloheximide (Chx) to inhibit protein synthesis. The cells were collected at the 
indicated time for the assay of ODC activity. (D) Control cells and isoproterenol-treated 
cells (10 µM) were incubated 2 h in the absence of presence of a10 µM concentration of 
the proteasome inhibitor MG132. The cells were then collected and ODC was assayed 
in cell extracts. Results are means ± s.e.m. of three to five measurements. 
 
 
 
 
 
 
 46 
0
25
50
75 *
O
D
C
 a
c
ti
v
it
y
 (
U
/m
g
)
AMPK
P-ACC
-actin
   
   
   
   
   
   
   
   
   
   
   
C
tr
l
   
   
   
   
   
   
   
   
   
   
   
   
  I
S
O
   
   
   
   
   
   
   
 IS
O
 / 
si
R
N
A
 L
uc
   
   
   
   
   
   
   
 I 
S
O
 / 
si
R
N
A

1
+

2
   
   
   
   
   
   
   
   
   
   
   
  I
S
O
 / 
si
R
N
A

1
   
   
   
   
   
   
   
   
   
   
   
   
  I
S
O
 / 
 s
iR
N
A

2
0
20
40
60
No siRNA
siRNA AMPK 1+2
siRNA Luc
 Ctrl       ISO      NE      PE
O
D
C
 a
c
ti
v
it
y
 (
U
/m
g
)
A
B
C AMPK
Akt
ERK 1/2
   
   
  C
tr
l
 s
iR
N
A
 L
u
c
 s
iR
N
A

1
+

2
 
 
Figure 3.  AMPK knock-down by siRNA causes an increase in ODC activity in 
isoproterenol-treated H9c2 cardiomyoblasts.  (A) The cells were transfected with a 
control siRNA against luciferase (Luc), or AMPKα1 plus AMPKα2 siRNAs, or 
AMPKα1 siRNA, or AMPKα2 siRNA. The cells were then  incubated in the absence or 
presence of 10 µM isoproterenol. The amount of AMPKα and phospho-ACC was 
determined after 1 h, whereas ODC activity was measured after 2 h of isoproterenol 
treatment. Results of ODC activity are means ± s.e.m. of three determinations, whreas 
the blots are representative of three experiments. (B) H9c2 cells transfected with the 
luciferase siRNA (Luc) or AMPKα1 plus AMPKα2 siRNAs, were incubated for 2 h in 
the absence or presence of 10 µM Norepinephrine (NE), or  isoproterenol (ISO), or 
phenylephrine (PE), then ODC activity was measured in cell extracts. (C) The contents 
of AMPKα, Akt, and ERK 1/2 were determined in cells transfected  with the luciferase 
siRNA (Luc) or AMPKα1 plus AMPKα2 siRNAs. 
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CHAPTER 3: ADIPOQ SNP45 ASSOCIATED WITH LEAN BODY 
MASS IN PHYSICALLY ACTIVE NORMAL WEIGHT 
ADOLESCENT GIRLS  
 
INTRODUCTION 
 
Obesity research has lead to a change in viewing fat mass instead of as dead 
weight and fat storage, but as an endocrine organ able to secrete hormones, termed 
adipokines, that affect metabolism and inflammation.  Adiponectin is a recently 
discovered adipokine that is specifically and highly expressed in human adipose tissue 
(Maeda et al., 1996). Adiponectin is a 247-amino acid peptide with a collagenous 
domain at the n-terminus and a globular domain that shares substantial homology with 
the subunits of complement factor C1q (Hu et al., 1996; Nakano et al., 1996; Scherer et 
al., 1995). What makes adiponectin a particularly interesting adipokine is that 
population studies show that while the majority of secreted hormones increase as fat 
mass increases, adiponectin, on the other hand in inversely related with fat mass, and its 
decrease is independently associated to the metabolic syndrome (Stenholm et al. 2010; 
Gnacinska et al., 2009).  
Data from human studies indicate that adiponectin has insulin-enhancing as well 
as anti-inflammatory actions (Kadowaki and Yamauchi, 2005). Adiponectin levels are 
markedly reduced in obese/diabetic mice, and injection of the adiponectin globular 
domain to these animals ameliorates insulin resistance, an effect that can be ascribed to 
an enhancement of fatty acid– oxidation in skeletal muscle and a decrease of hepatic 
gluconeogenesis mediated by AMP-activated protein kinase (Yamauchi et al., 2001; 
Maeda et al., 2002; Berg et al., 2001; Combs et al., 2004). Furthermore, adiponectin 
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knockout mice show increased susceptibility to diet-induced insulin resistance as well 
as injury-induced arterial stenosis and neointimal formation. Although, the decrease in 
adiponectin is due to underlying disease processes, there is belief that 
hypoadiponectinemia is a determinant factor rather than a consequence of these 
conditions (Menzaghi et al., 2007).  
The specific gene coding for adiponectin, officially named ADIPOQ, is placed 
on chromosome 3q27.  ADIPOQ  includes three exons, spanning a total of 16 kb of 
genomic sequence. Hara et al. (2002)
 
were the first to genotype the ADIPOQ in search 
of specific loci related to obesity, adiponectin levels, and diabetes mellitus. They 
reported that two single nucleotide polymorphism (SNP), +45G/T and +276T/G, were 
related to diabetes mellitus, and that specifically the SNP 276 is also related to 
adiponectin serum levels as well as obesity, in the Japanese population (Hara et al., 
2002). Upon this discovery, these specific loci have been investigated in many other 
cultural and racial populations, Korean (Hwang et al., 2009), elderly (Yang et al., 2007), 
Asian Indians (Vismaleswaran et al., 2008), white Caucasian and African Americans 
(Woo et al., 2006), Pima Indians (Vozarova de Courten et al., 2005) and obese children 
(Bouatia-Naji et al., 2006).   
These two SNP‘s are reported to be statistically different from one another in 
obese children independent of their fat mass and have also been found to be related to 
insulin resistance (Bouatia-Naji et al., 2006; Verduci et al., 2009); it is imperative to 
define the factors that lead to childhood obesity in efforts to prevent and to also avert 
adult obesity. Menzaghi et al. (2007) suggested that adiponectin is a determinant factor 
in the development of obesity and consequently the metabolic syndrome. If this 
statement is true and these polymorphisms genetically predispose individuals to develop 
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metabolic syndrome, these two sites can be a future target for gene therapy. Therefore, 
the aim of this study was to determine if these two polymorphisms (+45 T/G and +276 
G/T) are indeed determinants in the development of metabolic disorders or if they are 
secondary to other confounding factors. To do so we have selected an adolescent female 
population devoid of any metabolic diseases or confounding factors, such as obesity or 
inactivity in order to better attribute any findings to the genotype effects; a sample in 
which we have previously examined other variables associated with cardiovascular and 
metabolic health (Gruodyte et al 2010). 
MATERIALS AND METHODS  
Subjects 
This cross-sectional study involved 170 healthy adolescent girls, aged 13-15 years, 
recruited from different schools and sport clubs in Estonia as described by Gruodytė et 
al. (2010).  All girls were healthy and active participants of various types of physical 
activity. In order to exclude any confounding factors that might influence metabolic 
health we strictly recruited participants that were free from present or past diseases 
known to affect metabolism, and they did not used oral contraceptives, and were non 
smokers, two factors discovered to vary adiponectin serum levels (Luque-Ramírez et al., 
2009;  Kawamoto et al.,2010). Girls were also asked not to change their eating habits. 
Each girl and relative parent (or legal guardian) received a full written description of the 
nature of the study and signed an informed consent releasing the child to participate in 
the study. The study was approved by the Medical Ethics Committee of the University 
of Tartu (Estonia). 
Anthropometry and sexual maturation 
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Body height was measured to the nearest 0.1 cm using the Martin‘s metal 
anthropometer. Body mass of the girls, wearing light clothes and no shoes, was 
measured using medical balance scale (A&D Instruments Ltd, UK) to the nearest 0.05 
kg. Body mass index (BMI) was calculated (kg/m
2
). Pubertal development of the 
participants was assessed by self-report using an illustrated questionnaire of pubertal 
stages according to the criteria of Tanner (Tanner et al., 1962) which has been 
previously validated (Matsudo and Matsudo, 1994) and used in previous studies 
(Jurimae et al., 2006). The girls were given photographs, figures and descriptions of 
breast and pubic hair development stages, and asked to choose the one which most 
accurately reflected their appearance. If a disagreement between the development of 
breast and pubic hair was found, the final decision was made according to the breast 
(Matsudo and Matsudo, 1994; Jurimae et al., 2006). The girls were also asked if they 
had experienced menarche.  
Body Composition 
Fat scan mode was used on dual-energy X-ray absorptiometry (DXA; DPX-IQ, Lunar 
Corporation, Madison, WI, USA). Participants were scanned in light clothing while 
lying flat on their backs with arms at their sides. Standard subject positioning were used 
for total body measurements and analyzed using the extended analysis option. DXA 
measurements and results were evaluated by the same examiner. Coefficients of 
variations for body composition parameters were less than 2%. 
Blood analysis 
Venous blood samples to determine the concentration of adiponectin and insulin, as 
well as glucose were drawn between 0730 and 0830 a.m. after an overnight fast. For 
those girls who had menarche, the fasting blood samples were drawn in the early 
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follicular phase of the menstrual cycle, i.e. days 5-7 after menstrual bleeding started 
(Soot et al., 2006). The whole blood and serum was separated and stored at -20 °C for 
later analysis. The levels of total adiponectin concentration were analyzed  using ELISA 
kits (AdipoGen Aspen Haus, Germany). The intra- and interassay coefficients of 
variation (CVs) for adiponectin were less than 5%. The concentrations of insulin were 
analyzed on Immulite 2000 (DPC, Los Angeles, CA, USA). The intra- and interassay 
CVs were less than 5% and 12%, respectively, at an insulin concentration of 6.6 
µIU/ml. Glucose concentration was measured using the Hexokinase/Glucose-6-
Phosphate Dehydrogenase method with a commercial kit (Boehringer, Mannheim, 
Germany). In addition, the insulin resistance index was calculated using homeostasis 
model assessment (HOMA): fasting plasma insulin (µIU/ml) x fasting plasma glucose 
(mmol/l)/22.5 (Matthews et al., 1985). The greater HOMA values indicate the greater 
level of insulin resistance. 
Genotyping 
 
Genomic DNA for analyses was extracted from 1ml of the subjects‘ whole blood using 
QIAamp DNA Blood Midi Kit (Qiagen, Germany). DNA was prepared for 
amplification adding forward and backward primers with Master Mix (Solis Biodyne, 
Estonia). SNP +45 (T/G) in the ADIPOQ gene was genotyped by the amplification of 
genomic DNA using the following primers: forward, 5´-GCA GCT CCT AGA AGT 
AGA CTC TG-3´and reverse, 5´-TCT GTG ATG AAA GAG GCC AG-3´ (DNA 
Technology A/S, Denmark).  The PCR cycling was performed in a Biometra T Gradient 
Thermoblock (Biometra, Germany) as follows: 94 C for 10 min, 42 cycles of 30s at 94 
C, 30s at 57 C, 30 s at 72 C, 10 min extension step at 72 C, lid temperature 98 C. The 
PCR fragment was digested with the enzyme SMAI (Fermentas, Vilnius, Lithuania) at 
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30 C for 16 h.  SNP +276 (G/T) in the ADIPOQ gene was genotyped by the 
amplification of genomic DNA using the following pair of primers: forward, 5´-TCT 
CTC CAT GGC TGA CAG TG-3´and reverse, 5´-AGA TGC AGC AAA GCC AAA 
GT-3´(DNA Technology A/S, Denmark). The PCR cycling was performed as follows: 
94 C for 10 min, 35 cycles of 30s at 94 C, 30 s at 55 C, 30s at 72 C, and 10 min 
extension step at 72 C. The polymorphism was typed using the enzyme BsmI 
(Fermentas, Vilnius, Lithuania) at 37 C for 16 h. Restricted products were analyzed by 
electrophoresis in 1.5% agarose gel. The agarose gel was then stained with ethidium 
bromide and exposed under UV light (Uvitec, England) in order to visualize the 
digested fragments. 
Statistical analyses 
The independent segregation of alleles was tested for the Hardy-Weinberg equilibrium 
with a X
2
 test,  and both genotypes were considered consistent. Normality of 
adiponectin, insulin, fat, and lean body mass were controlled by one sample 
Kolmogorov-Smirnov test. If analyses were p>0.05 further analyses were parametric. If 
on the other hand the p<0.05 in the KS test, analyses were treated with non parametric 
measures. To determine differences between genotype group for normally distributed 
BMI, fat mass, lean body mass, adiponectin, and glucose levels, a one way analysis of 
variance (ANOVA) was performed, and for the non normally distributed values, insulin 
and HOMA index, Mann-Whitney U test was applied. Tests were not adjusted and 
adjusted for fat mass, age. All statistical analyses were performed with SPSS statistical 
package, version 10.0 (SPSS Inc., Chicago, IL, USA).  
RESULTS 
General characteristics of the subjects 
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General characteristics of the 170 adolescent female subjects are presented in Table 1.  
Mean values for fat mass, lean body mass, fasting glucose, and adiponectin serum levels 
were all within reference ranges and were normally distributed as per Kolmogorov-
Smirnov test. Insulin and HOMA values were significantly different from Kolmogorov-
Smirnov test and therefore not considered as normally distributed data.  
 
Frequency of the 45T/G and 276G/T ADIPOQ polymorphisms 
 
Frequency of each polymorphism in the population is reported in Table 1. These 
genotype distributions were in Hardy-Weinberg equilibrium (P = .598 at 45T/G, P = 
0.102 at 276G/T). 
Pearson and Spearman rho correlation of HOMA and serum adiponectin with 
anthropometric parameters and metabolic variables 
 
We found that in this rather lean population there was no significant correlation between 
adiponectin and fat mass and BMI as expected, but only a tendency: fat mass (r=-0.154, 
p= 0.056), BMI (r= -0.147, p= 0.059). Also reported is a negative correlation between 
HOMA and age (r= -0.177, p= 0.032) (Table 2).  
Metabolic and anthropometric parameters according to Tanner Stage 
 
Metabolic and anthropometric parameters according to genotype 
 
There were no genotype-related differences in Tanner stage, BMI, fat mass, 
adiponectin, glucose, insulin, and HOMA values at positions 45 and 276. However 
compared with homozygous TT carries, TG carries on position 45 had lower lean body 
mass (TT 41.1 ± 5.2; TG 36.9 ± 5.4, P=0.012 ) (Table 3).  
DISCUSSION AND CONCLUSIONS 
The main finding of the current study was that there were no Tanner stage, BMI, 
fat mass nor biochemical parameters differences among genotype groups in our normal 
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weight population as reported in other studies; however, G allele carriers of the 45 G/T 
genotype had significantly lower lean body mass compared to TT genotype (36.9±5.4 
kg and 41.1±5.2 kg, respectively; p<0.05).  
To control for any possible effect of puberty on other metabolic factors Tanner 
stage mean was determined for each genotype.  Studies shows there is an increase in fat 
mass as Tanner stage increases from 1-5 (Vink et al., 2009); there were no differences 
in Tanner stage among genotype groups in our population (p>0.05), allowing us to 
exclude any pubertal effect on any significant changes found among genotype.   
In the preceding articles concerning subjects afflicted by one or more than one 
component of the metabolic syndrome irregardless of age or ethnicity, the 45 T/G was 
associated with adiponectin levels and 276 G/T was related to insulin resistance. 
Specifically, the G allele of SNP 276 G/T was found to be associated with low plasma 
adiponectin levels and higher insulin resistance index in obese Japanese individuals as 
well as in obese children (Hara et al., 2002; Bouatia-Naji et al., 2006). Additionally, 
subjects with the G/T or G/G genotype at position 45 were reported to have a 
significantly higher risk for type 2 diabetes in the obese Japanese population (Hara et 
al., 2002.). However, just as in our study, none of the associations between 
polymorphism and various risk factors were present in the normal weight subjects (Hara 
et al., 2002; Jang et al., 2005). Furthermore, in the meta-analysis conducted by 
Menzaghi et al. (2007), in which the sample size was over 2,000 individuals, no 
relationships between the aforementioned genotypes and metabolic risk factors were 
found in the subjects with normal BMI. Since our results confirm Menzaghi et al. 
(2007), findings regarding normal weight individuals. Although the power of our study  
was rather low (average 0.45), therefore increasing the possibility that the null 
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hypothesis,  no difference among groups, is false,  our findings or lack of significance 
difference of any metabolic parameters among genotype groups is in line with research 
published considering our population only consisted of lean subjects.  We therefore 
stand by our results considering that all previous published studies with a stronger 
power support these findings. We can then conclude that the  ADIPOQ polymorphisms 
276 G/T and 45 T/G do not seem to be determinants of the metabolic syndrome in 
normal weighted healthy subjects, and that the effects of these polymorphisms observed 
in obese populations are secondary to other confounding factors, such as diet and 
physical activity.  
 Although, there was no significant relationship between the metabolic risk 
parameters (BMI, HOMA, adiponectin levels) and the polymorphisms analyzed in our 
sample of normal weight active adolescent females, there was a significant difference in 
lean body mass between genotypes, expressly the SNP +45 G/T.  Subjects who had the 
G allele substitution on site 45 had significantly lower lean body mass when compared 
with subjects with the homogenous TT wild type genotype (TG:36.90/TT:41.07 kg, 
P=0.012). Similar findings are not found in the literature, because to date all previous 
published studies have not reported lean body mass, but instead BMI or other 
anthropometric measures of metabolic health (waist circumference, percent body fat) 
when investigating these two genotypes. BMI, however, is not suitable to be used to 
predict fat mass in non obese subjects (Freedman et al., 2009) because increase in BMI 
can be caused by increase in lean body mass. Although the other studies main focus was 
differences between the obese population and respective controls, it would have been 
more precise, to have calculated fat mass and lean body mass independently, especially 
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since adiponectin is produced by adipocytes and because they did have normal weight 
individuals as part of their cohort.   
The significance of our novel relationship found, G allele at site 45 was 
associated to a decrease in lean body mass, lies in the fact that previous studies have 
showed that the G allele (both G/T and GG genotype) at site 45 was associated with an 
increase risk to Type II diabetes (Hara et al., 2002).  Not only have cross sectional 
studies seen this increase in risk for diabetes in G allele carries on site 45 trend, but as 
well as prospective studies (Fumeron et al., 2004; Tso et Al., 2006; Zacharova et al.,  
2005). Menzaghi et Al (2007) did not however confirm this association, and explained 
this difference between findings on the environmental and genetic factors seen in the 
various population in the cross sectional studies; Menzaghi et Al (2007)  was unable, 
however, to explain the fact that the prospective population studies did indeed find the 
aforementioned correlation, while their statistical analysis did not.  This question mark 
regarding this specific association leaves open the possibility that this association does 
indeed exist, but possibily throught an indirect pathway, not yet discovered.  
Our findings offer a possibile hypothesis as to the fact the the G allele on site 45 
could lead to the increasd risk of Type II diabetes through a decrease in lean body mass. 
It has been shown that increase in muscle mass leads to an improved glucose 
metabolism (List et al., 2009) and that resistance training is more effective in treating 
insulin resistance and type 2 diabetes mellitus than aerobic exercise (Winnick et al., 
2008). Further, it has been found that electro-stimulated muscle movement in spinal 
cord patients improved their insulin resistance since the cause of the type 2 diabetes 
mellitus in the spinal cord in injured population is due to the extensive amount of 
atrophy in their muscles (Winnick et al., 2008). Physiologically, an increase in muscle 
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mass is associated with a high concentration of GLUT-1 and GLUT-4 which are also 
associated with higher insulin sensitivity and glucose metabolism (Jeon et al., 2002).  
Aside from the muscular physiology demonstrating the key role of lean body 
mass in the prevention of Type II diabetes, there are also biochemical studies that 
demonstrate a direct role of adiponectin and muscle metabolism. Iwabu et al (2010) 
reported that adiponectin caused an increased activity in the SIRT-1, AMP-activated 
kinase (AMPK) phosphorylation , peroxisome proliferator-activated receptor-  
coactivator (PGC)-1   deacetylation, mitochondrial biogenesis, increase oxidative 
metabolism, increase insulin sensitivity. Such pathway was inactive when adiponectin 
stimulus was given to muscle adiponectin receptor knock-out mice leading to insulin 
resistance (Iwabu et al., 2010).   Evidence that correct muscle metabolism in imperative 
to insulin sensitivity (List et al., 2009, Winnick et al., 2008, Jeon et al., 2002) and that  
adiponectin has an potent role in the muscle metabolism by increasing mitochondrial 
activity and biogenesis through the deacetylation of PGC-1   (Iwabu et al., 2010) and 
the well documented translocation  of glucose transporter type (GLUT)-4  and 
expression to the cell surface via AMPK phosphorylation (Iwabu et al., 2010; Parks et 
al.,  2009; Li J et al.,2004).  Our findings therefore suggest that the plausible hypothesis 
for the increased risk in type 2 diabetes mellitus seen in the population that carry the G 
allele at site 45 of ADIPOQ can be due to a decrease in lean body mass, sign of 
decrease muscle metabolism, and not to the genotype itself.  
A valid limitation of this study that should be addressed is the size of our cohort. 
The natural frequency of the ADIPOQ polymorphism in Caucasians is (Lilioja et al., 
1987)
 
resulted in a small number of participants genotyped with the homozygous allele 
substitution: 11 subjects found with the TT genotype at site 276 and no subjects were 
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found to have the homozygous GG substitution at site 45 (natural frequency of GG 
genotype is 3.2%); however, results reported were shown to be statistical significant. A 
presence of a sufficient amount of subjects that contained the homozygous G 
substitution genotype could have revealed other valid relationships or even strengthened 
the relationship found between the G allele and lean body mass and not just the GT 
genotype.  For this reason, it would be necessary to confirm our findings in a 
sufficiently large sample size that guarantees a sufficiently statistical large amount of 
subjects that have the homozygous G substitution on site 45.  Also, although to date no 
studies have been conducted, possibly due to the difficulty of obtaining this type of 
invasive data on a population large enough to conduct a genotype study, it would be of 
even greater importance to evaluate biochemical parameters, markers of mitochondria 
metabolism among various genotype groups. 
In conclusion, the relationship between lean body mass, risk of insulin 
resistance, and SNP 45 T>G should be further investigated. The confirmation of our 
theory that the increase in risk of diabetes seen in the obese population G allele 
substitution at site 45 is due to decreased muscle metabolism, expressed by the decrease 
in lean body mass, present in carries of this genotype could lead to the distinguishing of 
individuals who have the propensity of having low lean body mass to thereafter 
prescribe resistance training from an early age to therefore prevent type 2 diabetes in 
adulthood.    
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TABLES 
 
 
Table 1 Summary of parameters in peripubertal and pubertal 
 adolescent girls (n=170)     
    Mean ±SD    Frequencies (%) 
Phenotype measures           
Age (yrs)  14.03 ±1.07    
Height (cm)  164.64 ± 7.38    
Weight (kg)  54.30 ± 8.77    
BMI (kg/m
2
)  20.00  ± 2.50    
Fat mass (kg)  13.23 ± 5.23    
Lean body mass (kg)  40.70 ± 5.31    
Adiponectin (µg/ml)  14.76 ± 6.59    
Insulin (µIU/ml)  6.32 ±4.01    
Glucose (mmol/l)  4.86± 0.39    
HOMA  1.38±0.91    
Tanner stage (1/2/3/4/5)    1.2/5.4/15.5/64.9/13.1  
Genotype ADIPOQ     
 
 
SNP 276 G>T      
% GG/GT/TT    46.3/47.9/5.9  
SNP 45 T>G      
% TT/TG/GG       92.6/7.4/0   
 
 
 
 
 
 
 
 
Table 2 Peason and Spearman rho bivariate correlation of  
Adiponectin and HOMA values with metabolic parameters 
  Adiponectin HOMA 
  r p r p 
 BMI   -0.147   0.059   0.13   0.116  
 Fat mass   -0.154   0.056   0.017   0.847  
 Lean body mass   -0.004   0.958   0.003   0.97  
 Insulin   0.071   0.274   0.988   <0.001  
 Glucose   0.09   0.25   0.426   <0.001  
Age   -0.177,  0.032 
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CHAPTER 4: ASSOCIATION OF COMMON VARIANTS IN THE 
ADIPONECTIN GENE WITH THE RELATIONSHIPS BETWEEN 
SERUM ADIPONECTIN, ESTRADIOL LEVELS AND BONE 
DENSITY IN PHYSICALLY ACTIVE GIRLS 
 
INTRODUCTION  
 
Females have any interesting relationship with estradiol and adiponectin. Although 
different, one a sex hormone and the other  an adipocytokine that is specifically and 
highly expressed in human adipose tissue (1), both, upon puberty, are present at a higher 
concentration in females when compared to males (2). Females have a 15% higher 
adiponectin serum level when compared to their male counterpart (3)
 
and both seem to 
play a protective role in preventing against osteoporosis and cardiovascular disease (4-
8).  
Osteoporosis is a disease in which bone mineral density (BMD) is reduced, bone 
microarchitecture is disrupted, and the amount and variety of proteins in bone is altered. 
Bone is in constant dynamic process of formation and resorption. The imbalance that 
occurs after menopause leads to osteoporosis (9). Osteoporosis may be caused not only 
by bone mineral loss in adulthood, but also by failing to accumulate an optimal bone 
mass during childhood and adolescence (10). It is known that regular high-impact 
weight-bearing physical activity (such as sport games, dance, gymnastics, running, or 
jumping exercises) during puberty has beneficial effect on growing bone by increasing 
its formation (11, 12). 
Both estradiol and adiponectin biochemically have resulted to play an important 
role in bone health.  Estradiol diminishes oxidative stress in bone and bone marrow, 
attenuates the generation of osteoblasts, and decreases the prevalence of mature 
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osteoblasts apoptosis (13, 14). Adiponectin receptors (AdipoR1 and AdipoR2) have 
been reported to be expressed in human osteoblasts (15, 16) and osteoblast-like cells 
(17). Adiponectin mRNA expression and adiponectin secretion increases during the 
differentiation of human osteoblasts in culture (16). Although the biological findings 
suggest an adiponectin positive effect on bone health, population studies that have 
investigated serum adiponectin levels and bone mineral density have surprisingly 
reported a negative and independent relationship between adiponectin and bone mineral 
density, in post menopausal women (18), anorexic girls (19), and middle aged men (20). 
However, these previous studies fail to investigate the plausible interaction between 
estradiol and the negative relationship between adiponectin and bone density, and failed 
to explain why the relationship found in cohort studies contradict biological findings 
(21).  
 To date, two studies have investigated the gene effect of the adiponectin gene 
(ADIPOQ) (location 3q27.3) on bone health, however reporting opposing results. Lee et 
al. reported the G allele in position 45 favored a significant decrease in BMD in an adult 
Korean Female population (mean age 51.4 yrs), independent of age, while they found 
no halotype effect (22).  On the contrary, Zhang et al. (2007) population study reported 
no gene effect of either SNP 45 or 276 on BMD, but instead found a strong gene effect 
on the T-T/T-T  halotype on postmenopausal lumbar spine BMD
 
(23).  
Both studies regarding this topic concentrated on a population at which bone 
formation is either stable or decreasing (22,23).   It is of our interest to understand the 
relationship between adiponectin and estradiol and bone health by means of optimal 
accrual, and to determine if optimal  accrual is effected by ADIPOQ polymorphisms, as 
reported by Lee et al. (2006) or Zhang et al. (2007). With weight bearing exercise being 
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such an important component to bone formation we have specifically chosen a cohort of 
physically active adolescent females in whom we have previously examined other 
variables associated with bone metabolism such as bone mineral density and content, 
lean and fat mass, puberty stages, estradiol plasma, and adiponectin serum levels (24) to 
therefore truly understand the magnitude of any genetic effect revealed by this study. 
MATERIALS AND METHODS  
Subjects 
 This cross-sectional study involved 170 healthy adolescent girls, aged 13-15 
years, recruited from different schools and sport clubs in Estonia as described by 
Gruodytė et al. (24). All girls were relatively healthy and active, participants of various 
types of physical activity (swimming, cross country skiing, rhythmic gymnastics, team 
sports, running). All participants were free from present or past diseases known to affect 
skeletal metabolism, none of the girls were receiving medications known to affect bone, 
and they did not used oral contraceptives. Girls were also asked not to change their 
eating habits. Each girl and her parent (or legal guardian) received a full written 
description of the nature of the study and signed an informed consent for the 
participation in the study. The study was approved by the Medical Ethics Committee of 
the University of Tartu (Estonia). 
Anthropometry and sexual maturation 
Body height was measured to the nearest 0.1 cm using the Martin‘s metal 
anthropometer. Body mass of the girls, wearing light clothes and no shoes, was 
measured using medical balance scale (A&D Instruments Ltd, UK) to the nearest 0.05 
kg. Body mass index (BMI) was calculated (kg/m
2
). Pubertal development of the 
participants was assessed by self-report using an illustrated questionnaire of pubertal 
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stages according to the criteria of Tanner (25), which has been previously validated (26) 
and used in previous studies (27). The girls were given photographs, figures and 
descriptions of breast and pubic hair development stages, and asked to choose the one 
which most accurately reflected their appearance. If a disagreement between the 
development of breast and pubic hair was found, the final decision was made according 
to the breast (26, 27). The girls were also asked if they had experienced menarche.  
Bone mineral density 
Bone mineral density (BMD) (g/cm
2
) and bone mineral content (BMC) (g) at femoral 
neck and lumbar spine (L2-L4) were measured using dual-energy X-ray absorptiometry 
(DXA; DPX-IQ, Lunar Corporation, Madison, WI, USA) equipped with proprietary 
software, version 3.6. Participants were scanned in light clothing while lying flat on 
their backs with arms at their sides. The fast scan mode and standard subject positioning 
were used for total body measurements and analyzed using the extended analysis 
option. DXA measurements and results were evaluated by the same examiner. 
Coefficients of variations for the femoral neck and lumbar spine BMD and BMC 
measurements were less than 2%.  
Blood analysis 
Venous blood samples to determine the concentration of selected hormones, adiponectin 
and estradiol were drawn between 0730 and 0830 a.m. after an overnight fast. For those 
girls who had menarche, the fasting blood samples were drawn in the early follicular 
phase of the menstrual cycle, i.e. days 5-7 after menstrual bleeding started (28). The 
whole blood and serum was separated and stored at -20 °C for later analysis. The levels 
of adiponectin concentration were analyzed using ELISA kits (AdipoGen Aspen Haus, 
Germany). The intra- and interassay coefficients of variation (CVs) for adiponectin – 
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less than 5% and 6%, respectively. The concentrations of estradiol were analyzed on 
Immulite 2000 (DPC, Los Angeles, CA, USA). The intra- and inter-assay coefficients of 
variation were less than 7%. 
Genotyping 
 
Genomic DNA for analyses was extracted from 1ml of the subjects‘ whole blood (blood 
withdrawal described above)  using QIAamp DNA Blood Midi Kit (Qiagen, Germany) 
DNA  was successfully extracted from all samples with a concentration ranging from 
10-50 ng/µl. DNA was prepared for amplification adding forward and backward 
primers with Master Mix (Solis Biodyne, Estonia) SNP +45 (T/G) in the ADIPOQ gene 
was genotyped by the amplification of genomic DNA using the following primers: 
forward, 5´-GCA GCT CCT AGA AGT AGA CTC TG-3´and reverse, 5´-TCT GTG 
ATG AAA GAG GCC AG-3´ (DNA Technology A/S, Denmark)  The PCR cycling was 
performed in a Biometra T Gradient Thermoblock (Biometra, Germany) as follows: 94 
C for 10 min, followed by 42 cycles of 30s at 94 C, 30s at 57 C and 30 s at 72 C, and 
ending with a single 10 min extension step at 72 C, with the lid temperature at 98 C. 
The PCR fragment was 367 bp in length and was digested with the enzyme SMAI 
(Fermentas, Vilnius, Lithuania) at 30 C for 16 h. Restriction products were analyzed by 
electrophoresis in 3 % agarose, and digestion produced allele G: 318+148bp and  allele 
T: 466 bp.  SNP +276 (G/T) in the ADIPOQ gene was genotyped by the amplification 
of genomic DNA using the following pair of primers: forward, 5´-TCT CTC CAT GGC 
TGA CAG TG-3´and reverse, 5´-AGA TGC AGC AAA GCC AAA GT-3´( DNA 
Technology A/S, Denmark). The PCR cycling was performed in a Biometra T Gradient 
Thermoblock (Biometra, Germany) as follows 94 C for 10 min, followed by 35 cycles 
of 30s at 94 C, 30 s at 55 C, and 30s at 72 C, and ending with a single 10 min extension 
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step at 72 C. The polymorphism was typed using the enzyme BsmI (Fermentas, Vilnius, 
Lithuania) at 37 C for 16 h. Restricted products were analyzed by electrophoresis 1.5% 
agarose gel. 
Statistical analyses 
The independent segregation of alleles was tested for the Hardy-Weinberg equilibrium 
using Χ2 test, and both genotypes were considered consistent. Normality of adiponectin, 
insulin, estradiol, fat, and lean body mass were controlled by one sample Kolmogorov-
Smirnov (KS) test. If analyses were p>0.05 further analyses were parametric. If on the 
other hand the p<0.05 in the KS test, analyses were treated with non parametric 
measures. To determine differences between genotype group for normally distributed 
adiponectin, bone content and density parameters, fat mass, and lean mass, ANOVA 
was performed. Mann-Whitney U and Kruskal-Wallis test was performed to determine 
if there were significant differences in estradiol serum level between genotype groups. 
Correlations of parametric parameters were done with Pearson‘s partial correlation and 
controlled for fat and lean mass, while non parametric correlations were tested with 
Spearmen rho. All statistical analyses were performed with SPSS statistical package, 
version 10.0 (SPSS Inc., Chicago, IL, USA).  
RESULTS 
 
General characteristics of study subjects 
General characteristics of the 170 adolescent female subjects are presented in Table 1.   
Mean values for fat mass, lean body mass, adiponectin serum levels, and all bone 
mineral content and density were all within reference ranges and normally distributed as 
per Kolmogorov-Smirnov test. Estradiol values were significantly different from 
Kolmogorov-Smirnov test and therefore not considered normally distributed data.  
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Frequency of the 45T/G and 276G/T ADIPOQ polymorphisms 
 
Frequency of each polymorphism in the population is reported in Table 1. These 
genotype distributions were in Hardy-Weinberg equilibrium (P = 0.598 at 45T/G, P = 
0.102 at 276G/T).  
Metabolic, Tanner stage, and anthropometric parameters according to genotype 
There were no genotype-related differences for Tanner stage, BMI, fat mass, percent 
body fat, adiponectin, and estradiol at position 45 and 276. However compared with 
homozygous TT carries, TG carries at position 45 had lower lumbar spine BMC (TT 
43.36 ± 9.54; TG 35.45 ± 6.54, P=0.008). Data presented in Table 2.  
Pearsonś and Spearmanś correlation between bone mineral content and density 
measurements, hormone levels and anthropometric parameters 
 
Correlation coefficients reported in Table 3 reveal that all anthropometric measurements 
are significantly correlated with all bone mineral content and density measurements. 
Lean body mass had the highest correlation coefficient to bone parameters than any 
other measurement. Adiponectin serum level was not significantly associated to any of 
the measurements presented, while estradiol was significantly negatively correlated with 
BMI (R=-0.27, P=0.001) and fat mass (R=-0.30, P=0.001) when tested for Spearman 
rho´s correlation.  
Pearson and Spearman rho correlation of serum estradiol and adiponectin with bone 
content and density parameters according to genotype 
 
Subjects were grouped by genotype and then correlation coefficients were calculated 
mass between estradiol and adiponectin while controlling for bone mineral content and 
density and  lean body mass and fat. There were no significant correlations between 
both estradiol and adiponectin, and bone health parameters when considering the whole 
sample, but when subdivided by genotype, significant relationships were revealed.  
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There was a significant correlation present between estradiol plasma levels and 
BMD total values when subjects were homozygous wild-type at position 276 when 
controlled for lean body mass and fat mass (Estradiol x BMD total R=0.26 P=0.049). 
There were also significant correlations between estradiol and bone parameters when 
subdivided by genotype at position 45. Estradiol and lumbar BMC (R=0.76, P=0.041), 
and femoral neck BMC (R=0.86, P=0.013), and femoral neck BMD (R=0.93, P=0,003), 
and total BMD (R=0.75, P= 0.05) were found significant when only subjects that were 
heterozygous TG were considered.  
 There was also an increase in significant correlations between adiponectin and 
bone parameters when subdivided by genotype. When controlled for fat mass and lean 
body mass there were significant correlations between adiponectin serum levels and 
lumbar BMC (R=0.336, P=0.004), femoral neck BMC(R=.25, P=0.036), total BMC 
(R=0.28, P=0.019), and lumbar BMD (R=0.25.P=0.037) in the homozygous wild-type 
GG group at position 276. When the polymorphism at position 45 was subdivided there 
were significant correlations present between adiponectin and lumbar BMC (R=0.20, 
P=0.021) and femoral neck BMC (R=0.17, P= 0.042) when subjects were homozygous 
wild-type TT. Data displayed in Table 4.  
DISCUSSION 
Our results suggest that there is an ADIPOQ gene effect in relation to bone 
parameters. Statistical analysis show that the presence of the T allele in position 45 
favors an  increase in lumbar spine bone mineral content (BMC) when compared to 
subjects with a G allele substitution (TT: 43.36± 9.54, TG: 35.45 ± 6.54, P<0.05). Both 
lean body mass and fat mass where controlled for when investigating the gene effect on 
the relationship between adiponectin and estradiol.  It was found that the G allele in site  
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45 and 276 favored the presence of a significant positive correlation between estradiol 
and bone mineral density (45: R= 0.75; 276: R= 0.26, P<0.05). The wild-type 
homozygous genotype in position 45 and 276 strengthens the positive correlation 
between adiponectin and various bone mineral content parameters and lumbar spine 
bone mineral density (45: R=0.21-0.22; 276: R=0.25-0.34; P<0.05). 
Our genotyping investigation supports the findings published by Lee et al. 
(2006), suggesting a novel relationship between genotype and bone parameters. More 
specifically the importance of the T allele at site 45 in predisposing subjects to have 
higher bone mineral content and density (22). We however did not find any halotype 
effect (data not shown) on bone mineral density, contrary to Zhang et al. (2007) findings 
(23).  
Estrogens are stated as being the biggest contributor to bone mineral acquisition 
during puberty in both males and females (29), and as expected there is a strong positive 
correlation found between estradiol levels, Tanner stage, and bone mineral parameters 
(data not presented); however, since there was no difference in total estradiol levels or 
tanner stage among gene group, it is possible to exclude the effect of estradiol and 
pubertal stage on the gene effect observed on lumbar spine BMC.  
We report a positive correlation present between BMI and body weight with 
bone mineral density and content, a correlation repeatedly supported in literature; 
however, we have also seen that from all anthropometric measures lean body mass is 
the best predictor of bone mineral density, findings supported by a cross sectional study 
in Sri Lanka (30). Reid et al. (1995) suggested that exercise is the cause for the 
dissociation between fat mass and bone mineral density (31), a characteristic found in 
our sample. Moreover, interestingly we also previously reported that T allele favored a  
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greater lean body mass (32), the same relationship found between polymorphism 45 and 
lumbar spine BMC with also lean body mass. The increase in lean body mass in this 
genotype group could very well explain the relationship found between genotype and 
bone mineral density in our physically active population (30,31). In addition, the 
importance of lean body mass is further supported by the fact, that although estradiol 
levels is considered to be the biggest contributor to bone formation in males and females 
(29) males still have a higher bone mineral density than females upon puberty even 
though both estradiol and adiponectin levels are higher in females than in males (3, 29, 
33). A possible explanation could be the increase in lean mass in the male population 
that usually accompanies puberty (34).  
This is the first study to date to report an ADIPOQ genetic effect on 
adiponectin´s and estradiol´s relative effect on bone mineral parameters. It would seem 
only obvious the existence of this relationship considering there is an increase in 
osteoporosis after the fall in estradiol and adiponectin levels present after menopause. 
Because this aforementioned relationship is also present between the increase in 
cardiovascular disease upon menopause, Yoshihara et al. (2009) were the first to 
investigate a possible genetic interaction between adiponectin and estradiol and risk for 
cardiovascular disease (35).  Contrary to our present study, Yoshihara et al. (2009) 
studied the genetic effect of the estrogen receptor (ER) polymorphism and found that 
ER polymorphism was related to adiponectin serum levels (35).  The results of this 
study along with those of Yoshihara et al. (2009) demonstrate the presence of a genetic 
interaction, although unclear, that exists between estradiol and adiponectin and their 
effects on bone and cardiovascular health (35). Since both hormones have anti-
inflammatory effects and both increase during osteoblast differentiation (7,13, 16), 
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findings suggest that the effect that either of these hormones have on bone and 
cardiovascular are not independent from one another and therefore, in future studies of 
bone and cardiovascular health, both hormones should be evaluated.  
Moreover, these findings also highlight the importance of lean body mass, and 
therefore exercise, which is why it would be opportune to follow this study with an 
experiment evaluating the effect of an exercise treatment on bone formation and the 
genotype effect of adiponectin, estrogen, and estrogen receptor polymorphisms, to help 
improve exercise prescription.  
A valid limitation of this study is the size of our cohort, visible in the fact that in 
total there were only 11 subjects found with the TT genotype at site 276 and no subjects 
were found to have the homozygous GG substitution at site 45. The absence of a 
genotype group restricted us from determining if the effect seen at site 45 is linked to 
the G allele or is it a genotype effect seen solely in the GT genotype group.  Although 
the power of our study was rather low (average 0.45), therefore increasing the 
possibility that the null hypothesis, no difference among groups, is false, our findings, 
or lack of significant difference of any metabolic parameters among genotype groups, is 
in line with research published. We therefore stand by our results considering that all 
previous published studies with a stronger power support these findings. It would be 
forthcoming to reconfirm the G allele in position 45 effects does indeed favor a decrease 
bone mineral density and does increase the correlation between estradiol and bone 
mineral density.   
In conclusion the ADIPOQ single nucleotide polymorphism 45 seems to have a 
direct effect of lumbar spine bone mineral content and an indirect effect on how both 
estradiol and adiponectin levels are related to bone mineral content and density. 
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TABLES 
 
Table 1 Summary of parameters in subjects (n=170)  
  Mean ±SD  Frequencies (%) 
Age (yrs) 14.03 ±1.07  
Height (cm) 164.64 ± 7.38  
Weight (kg) 54.30 ± 8.77  
Fat mass (kg) 13.23 ± 5.23  
Lean body mass (kg) 40.70 ± 5.31  
BMI (kg/m
2
) 19.98  ± 2.50  
BMC lumbar spine (g) 42.74 ± 9.52  
BMC femoral neck (g) 4.81  ± 0.77  
BMD lumbar spine (g/cm
2
) 1.09 ± 0.13  
BMD femoral neck (g/cm2) 1.04 ± 0.13  
Tanner stage (1/2/3/4/5)  1.2/5.4/15.5/64.9/13.1 
Hormonal Measures  
 
 
Adiponectin  (µg/ml) 14.76 ± 6.59   
Estradiol (pmol/l) 99.02 ± 104.68   
   
Genotype ADIPOQ   
SNP 276 G>T   
% GG/GT/TT  46.3/47.9/5.9 
SNP 45 T>G   
% TT/TG/GG   92.6/7.4/0 
BMI: body mass index 
BMD: bone mineral density 
BMC: bone mineral content 
   
Table 2 Means (± SD) and Ranks of phenotype measurements grouped by genotype 
  BMC l2-l4 BMC femo BMD l2-l4 BMD femo Adiponectin Estradiol 
  (g) (g) (g/cm2) (g/cm2)  (µg/ml) (pmol/l) 
SNP 276 
G>T       
GG 43.64 ± 9.59 4.88± 0.76 1.11± 0.14 1.05± 0.11 14.69 ± 5.99 122.21 ± 143.36 
GT 41.91± 9.51 4.75± 0.80 1.08± 0.13 1.03± 0.13 15.70 ± 7.52 82.71 ± 55.96 
TT 43.31± 10.37 4.8± 0.62 1.08± 0.14 1.01± 0.08 12.16 ± 5.26 77.78± 59.61 
SNP 45 T>G       
TT 43.36± 9.54 * 4.84  ± 0.78 1.10 ±0.13 1.04 ± 0.12 14.91 ± 6.65 99.85 ± 108.58 
TG 35.45 ± 6.54 4.44  ± 0.56 1.03 ± 1.03 1.0 ± 0.12 16.83 ± 7.91 104.22 ± 65.68 
*P<0.05  
BMC l2-l4: lumbar bone mineral content  
BMC femo: femoral neck bone mineral content 
BMD l2-l4: lumbar bone mineral density 
BMD femo: femoral neck bone mineral density 
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Table 3 Pearson´s and Spearman rho´s correlation between bone parameters and hormone levels,  
and anthropometric parameters       
  
BMCL2-
L4 BMC femo 
BMC 
tot 
BMD L2-
L4 
BMD 
femo BMDtot Adiponectin Estradiol 
  (g) (g) (g) (g/cm2) (g/cm2) (g/cm2)  (µg/ml) (pmol/l) 
BMI 0.35** 0.49** 0.53** 0.41** 0.35** 0.48** -0.15 -0.27** 
Lean body mass 0.78** 0.76** 0.85** 0.64** 0.66** 0.73** 0.004 -0.05 
Fat mass 0.39** 0.49** 0.57** 0.45** 0.38** 0.46** -0.15 -0.30** 
**p<0.01         
         
BMC l2-l4: lumbar bone mineral content  
BMC femo: femoral neck bone mineral content 
BMD l2-l4: lumbar bone mineral density 
BMD femo: femoral neck bone mineral density 
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GENERAL DISCUSSION AND CONCLUSIONS 
 
The articles presented above report  novel findings within their specific research sector.  
            The first article reports the metabolic signaling relationship between two SIRT1 
and AMPK. This study focused specifically on the response of SIRT1 to the α-
adrenergic agonist, phenylephrine,  in H9c2 cardiac myoblasts, a cell model of cardiac 
hypertrophy. After 24 and 48 h of phenylephrine treatment, SIRT1 expression and 
deacetylase activity were significantly increased.  SIRT1 upregulation by phenylephrine 
was not associated to changes in NAD
+
 levels, but was blocked by inhibitors of AMP-
activated Protein Kinase (AMPK), AraA or  STO-609, as well as by siRNA AMPK 
knockdown. When SIRT1 was inhibited with sirtinol or downregulated by siRNA, H9c2 
cell viability was significantly decreased following phenylephrine treatment, showing 
that SIRT1 improves cell survival under hypertrophic stress. Consequently we have 
proposed that the increase in SIRT1 activity and expression in H9c2 cells treated with 
phenylephrine is an adaptive response to the hypertrophic stress, mediated by AMPK, 
suggesting that adrenergic stimulation of heart cells, activates hypertrophic 
programming and also promotes a self-protecting and self-regulating mechanisms.  
          The second article reveals a mechanism that could be involved in the regulation of 
cardiac hypertrophy by AMPK: we have found that AMPK can modulate the activity of 
Ornithine decarboxylase (ODC). The upregulation of ODC, the key enzyme in the 
biosynthesis of polyamines, is a characteristic event in response to agents that induce 
cardiac hypertrophy. The question is why two apparently contrasting mechanisms are 
activated at the same time in heart cells committed to hypertrophy. We suspect that 
AMPK plays a regulatory role in the transition towards the hypertrophic phenotype. The 
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rapid activation of AMPK following adrenergic stimuli is probably due to the cells 
effort to guarantee itself energetic substrates in order to respond to an increase in ATP 
demand.  The lack of optimal nutritional conditions (energetic substrates) due to a 
prolonged activation of AMPK could instead contrast  the establishment of hypertrophy, 
possibly also by means of the negative modulation of ODC activity.   
In the Chapter 1 data are provided suggesting that adrenergic stimulation of heart cells 
along with the hypertrophic program also promotes self-protecting and self-regulating 
mechanisms . The modulation of ODC activity by AMPK well fits in this model, since it 
could represent a powerful self-regulatory mechanism. 
The other two articles investigated the influence that two single nucleotide 
polymorphisms (SNP) of the adiponectin gene (SNP +45T/G and +276G/T ) have on 
women‘s health parameter determinants specifically regarding cardiovascular and bone 
health.  The third article discusses the SNP role in the development of diabetes, because 
it has been suggested by other studies that the G allele substitution at site 45 increased 
the risk of its development in the population.  Our results suggest that the literature 
reported increase in the risk of diabetes in subjects that were G allele carries at site 45 in 
obese populations when compared to normal weight populations can be caused by a 
muscle mass difference. A more clear  vision of the relationship between SNP and 
diabetes was possible to disclose because the study was conducted on adolescent girls, a 
population that is void of many of the other confounding variables present in an adult 
population.  
The forth article was mainly focused on the prevention of osteoporosis by the 
studying factors affecting the proper accrual of peak bone mass during adolescence, 
mainly the interaction between ADIPOQ SNP, estradiol, and bone density.  It was found 
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that the G allele substitution on site 45 favored a greater bone mineral density, which 
can be explained by three hypothesis. One, that the SNP of ADIPOQ does 
independently influences the proliferation of osteocytes and thereby bone formation; 
two, that the SNP of the adiponectin gene influences muscle mass which indirectly 
influences bone formation; three, is that there is an interaction between the two 
plausible hypothesis stated prior. We also reported a weak, but present interaction 
between ADIPOQ SNPs and estradiol and bone density. Following, interpretation of this 
specific finding will be discussed.  
All four studies along with already published findings indicate how SIRT1, 
AMPK, adiponectin are related to each other, exercise and health.  It is already 
recognized that chronic exercise training causes an increase in  SIRT1 and AMPK 
activity, and adiponectin levels (10,21). Also AMPK is downstream of the adiponectin 
receptor AdipoR1 and AdipoR2, with a reported preference to AdipoR1 in skeletal 
muscle (23,27). However, it is of interest to reveal the relationship between these three 
factors and how they are associated to health and harm.  
Adrenergic stimulation is well known to be a key factor in cardiac hypertrophy. 
Hypertrophic changes occur in response to both alpha and beta adrenergic stimulation 
 in vitro. On a clinical level, down regulation of β-adrenergic receptors in heart failure 
as a compensatory mechanism elicited to protect the heart from too much sympathetic 
stimulation, and then becoming desensitized to adrenergic stimulation secondary to the 
uncoupling of these ARs from their downstream signaling pathways. Again following 
the reasoning that β-AR signaling is desensitized in heart failure, resulting in the need 
for higher doses of an agonist to achieve effective increases in myocardial contractility. 
On the contrary, one of the adaptations to exercise training is the increase in adrenergic 
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sensitivity. There is an increase in receptor density and a decrease in the amount of 
epinephrine released at a given work load.  
As reported in literature, adrenergic stimulation as well as exercise increases not 
only  SIRT1 activity but also SIRT1 transcription and protein expression (29).  This has 
been consistently found in in-vitro studies as well as in in-vivo studies conducted on 
humans and mice. This increase in SIRT1 function in response to exercise and 
adrenergic stimulation is however only seen acutely, followed by an increase in 
mitochondrial biogenesis marked by the chronic increase of cytochrome C and citrate 
synthase (29), and markers of proliferation and hypertrophy in-vivo. These biochemical 
adaptations in response to adrenergic stimulation and exercise seen following the 
increase in  SIRT1 activity are the same seen following the increase in  AMPK activity.  
Suggesting not only a close relationship between both SIRT1 and AMPK,  but also that 
the changes that occur in response to exercise can be explained as a signaling response 
to the adrenergic stimulation patterns seen during chronic and acute bouts of exercise. 
Therefore epinephrine release not only causes an immediate responses to cope with 
increases in demand during exercise, such as increasing  heart rate and force, but also 
signals other cellular changes that have a more chronic effect so to allow a more 
efficient response to a future increase in demand.    
Adiponectin plasma levels is generally viewed as a positive indicator of health. 
Negatively correlated to fat mass, and increases according to intensity training (30) as 
well as increasing in response to training independent of fat mass changes (30). We 
published that the adiponectin gene polymorphism had a novel relationship to lean body 
mass. Although this is the first time that the adiponectin gene had been linked to muscle 
mass, previous studies have already reported an increase in muscle cell proliferation in 
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response to adiponectin (23,31), thereby strengthening the plausible relationship 
between adiponectin and muscle cell. Administration of adiponectin has  also been 
shown to cause glucose-lowering effects and ameliorate insulin resistance in mice,
. 
and 
adiponectin-deficient mice exhibit insulin resistance and diabetes (32).  This insulin-
sensitizing effect of adiponectin seems to be mediated by an increase in fatty acid 
oxidation by the activation of AMP-activated protein kinase (AMPK) and also by 
peroxisome proliferator-activated receptor α (PPARα) (32). In contrast, the relationship 
between Adiponectin and SIRT1 is unclear. Banks et al. (2008) demonstrated that SIRT1 
overexpressed mice exhibited beneficial metabolic effects such as increase in insulin 
sensitivity, resistance to diabetes and hyperadiponectinemia (33). Later, Iwabu et al. 
(2010) reported that adiponectin exhibited its beneficial effects by causing an increase 
in SIRT1, thereby concluding that adiponectin regulates the AMPK/SIRT axis (34). The 
interaction between SIRT1 and adiponectin, as to which is upstream of the other, or if 
instead there is feedback mechanism, must still be elucidated.  
Literature reports a direct relationship between the adrenergic system and 
adiponectin. In vivo and in vitro studies report that adrenergic agonist significantly 
decrease adiponectin secretion (35). The decrease in adiponectin secretion  in response 
to adrenergic agonists along with the knowledge of catecholamine secretion in response 
to chronic and acute exercise explains  the increase in adiponectin serum levels after 
exercise training (decrease  in adrenergic basal activity) and the absence changes in 
adiponectin levels in response to acute exercise (increase in adrenergic activity to meet 
increase in physiological demand) (36). Concluding that adiponectin secretion is one of 
the many adaptive responses to exercise mediated by adrenergic signaling and not an 
immediate response to stress.   
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Contrary to the accepted belief that high adiponectin levels are an indication of 
health, it has also been paradoxically reported that high adiponectin levels is correlated 
with a negative prognosis of survival in chronic heart failure patients (37). It was 
subsequently found that beta- antagonist treatment in patients reduced adiponectin 
levels especially in non obese heart failure patients (38) and prognostic value of 
adiponectin level was severely diminished (39). This paradox can be explained if 
adiponectin levels are considered as a consequence to the adrenergic system‘s 
adaptations during exercise (described above) and a pathological state (high levels of 
adiponectin).  In heart failure patients there is an increase in plasma epinephrine levels, 
so one would expect a decrease in adiponectin levels, which is, however,  the exact 
opposite of what has been reported.  It is also well noted that there is a process of 
desensitization of the adrenergic response in heart failure patients, so in essence, 
although there is a lot of circulating epinephrine, since the receptors are not fully 
functional, it is as if there are low levels of epinephrine, consenting therefore the 
increase in adiponectin as seen in this specific population.  Essentially, adiponectin 
levels in heart failure patients is not a direct indicator of the patient‘s prognosis , as 
proposed by literature, but instead it is an indicator of the functional status of the 
adrenergic system, which is why treatment with beta blockers reduces the prognosis 
power of adiponectin levels (39).     
After the statement of such a hypothesis, one may ask then, what is the 
involvement of bone in this relationship, especially when science seems to be so 
specialized as to view health and the human body as a summation of independent cells, 
organs, and systems, instead of as a whole. Similar to that above described relationship 
between, adrenergic system and adiponectin with heart health, the literature reports 
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findings that can lead to a plausible relationship also between adrenergic system and 
adiponectin with bone health.  
It has been well documented clinically that there is an increase in osteoporosis 
and cardiovascular disease in females after  menopause, at which point there is a 
decrease in estradiol and adiponectin circulation levels (40,41). A simplistic conclusion 
that one can form is that there is an increase in disease because there is a decrease in 
what are recognized as protective hormones in terms of bone health (42-45).  However, 
a broader view of this complex picture is a better fit. Aside from having a decrease in 
estradiol and adiponectin after menopause, it is also well documented that there is an 
increase in sympathetic activity (46) , also when compared to males, premenopausal 
women have a lower sympathetic activity (47). The difference in sympathetic activity 
between male and females is dependent on the relative sex hormones  (47). The Syr 
locus located on the Y chromosome regulates tyrosine hydroxylase, an enzyme 
responsible for the production of nor-epinephrine, while 17  estradiol inhibits 
tyrosinase  activity, another enzyme necessary for the formation of norepinephrine (47) 
(Figure 7). 
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It is has also been reported that an effective clinical treatment for osteoporosis is the 
use of beta antagonists, since adrenergic activity increases absorption of bone (48). 
Again, as with cardiac health, one can hypothesize that the decrease in adiponectin seen 
at menopause can be due to the increase in sympathetic activity, since adrenergic 
stimulation has been reported to significantly decrease adiponectin release (35), and  
said increase in adrenergic activity  is caused by the decrease in estradiol levels (47).  
Further, exercise is a well noted method of ensuring bone health and density, by 
stimulating formation because of osteocytes role as mechano-sensory receptors — 
regulating the bone's response to stress and mechanical load.  Aside from the 
mechanical effect of exercise training on bone, one can also consider that there are 
beneficial effects that can be attributed to the fact that training causes a decrease in basal 
sympathetic activity, explaining why  which cycling training (non impact) increase bone 
density in spinal cord injured patients (49). The decrease sympathetic activity in 
response to training decreases its inhibitory effect on adiponectin; essentially training 
Figure 7 
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can warrant a similar effect to that of treatment with beta adrenergic antagonists .  This 
hypothesis can also help explain that although adiponectin and estradiol seem to work 
hand in hand, we found  a surprisingly a slight relationship (although significant) 
between ADIPOQ SNP and estradiol levels and bone density.  One can speculate that 
the missing link between the two hormones is the adrenergic system, a system that is 
connected to all parts of the body via nervous system (nor-epinephrine) and the 
circulatory system (epinephrine).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary Figure 1 
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Further research towards clarifying the relationship between SIRT1, AMPK, 
adiponectin, and the adrenergic system is crucial to better understand how to treat and 
prevent disease.   In the future, I would like to specifically investigate the role of 
calcium within the relationship, since calcium is needed for muscle contraction and cell 
signaling, and bone is the body‘s primary calcium reservoir.  
 
 
Summary Table 1 
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